

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 102, 204, 206, and 208 and by
6 adding Section 309.1 as follows:

7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

8 (Text of Section before amendment by P.A. 103-881)

9 Sec. 102. Definitions. As used in this Act, unless the
10 context otherwise requires:

11 (a) "Addict" means any person who habitually uses any
12 drug, chemical, substance or dangerous drug other than alcohol
13 so as to endanger the public morals, health, safety or welfare
14 or who is so far addicted to the use of a dangerous drug or
15 controlled substance other than alcohol as to have lost the
16 power of self control with reference to his or her addiction.

17 (b) "Administer" means the direct application of a
18 controlled substance, whether by injection, inhalation,
19 ingestion, or any other means, to the body of a patient,
20 research subject, or animal (as defined by the Humane
21 Euthanasia in Animal Shelters Act) by:

22 (1) a practitioner (or, in his or her presence, by his
23 or her authorized agent),

1 (2) the patient or research subject pursuant to an
2 order, or

3 (3) a euthanasia technician as defined by the Humane
4 Euthanasia in Animal Shelters Act.

5 (c) "Agent" means an authorized person who acts on behalf
6 of or at the direction of a manufacturer, distributor,
7 dispenser, prescriber, or practitioner. It does not include a
8 common or contract carrier, public warehouseman or employee of
9 the carrier or warehouseman.

10 (c-1) "Anabolic Steroids" means any drug or hormonal
11 substance, chemically and pharmacologically related to
12 testosterone (other than estrogens, progestins,
13 corticosteroids, and dehydroepiandrosterone), and includes:

- 14 (i) 3[beta],17-dihydroxy-5a-androstane,
15 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
16 (iii) 5[alpha]-androstane-3,17-dione,
17 (iv) 1-androstenediol (3[beta],
18 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
19 (v) 1-androstenediol (3[alpha],
20 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
21 (vi) 4-androstenediol
22 (3[beta],17[beta]-dihydroxy-androst-4-ene),
23 (vii) 5-androstenediol
24 (3[beta],17[beta]-dihydroxy-androst-5-ene),
25 (viii) 1-androstenedione
26 ([5alpha]-androst-1-en-3,17-dione),

- 1 (ix) 4-androstenedione
2 (androst-4-en-3,17-dione),
3 (x) 5-androstenedione
4 (androst-5-en-3,17-dione),
5 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
6 hydroxyandrost-4-en-3-one),
7 (xii) boldenone (17[beta]-hydroxyandrost-
8 1,4,-diene-3-one),
9 (xiii) boldione (androsta-1,4-
10 diene-3,17-dione),
11 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
12 [beta]-hydroxyandrost-4-en-3-one),
13 (xv) clostebol (4-chloro-17[beta]-
14 hydroxyandrost-4-en-3-one),
15 (xvi) dehydrochloromethyltestosterone (4-chloro-
16 17[beta]-hydroxy-17[alpha]-methyl-
17 androst-1,4-dien-3-one),
18 (xvii) desoxymethyltestosterone
19 (17[alpha]-methyl-5[alpha]
20 -androst-2-en-17[beta]-ol) (a.k.a., madol),
21 (xviii) [delta]1-dihydrotestosterone (a.k.a.
22 '1-testosterone') (17[beta]-hydroxy-
23 5[alpha]-androst-1-en-3-one),
24 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
25 androstan-3-one),
26 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-

1 5[alpha]-androst-3-one),
2 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
3 hydroxyestr-4-ene),
4 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
5 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
6 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
7 17[beta]-dihydroxyandrost-1,4-dien-3-one),
8 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
9 hydroxyandrostano[2,3-c]-furazan),
10 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
11 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
12 androst-4-en-3-one),
13 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
14 dihydroxy-estr-4-en-3-one),
15 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
16 hydroxy-5-androst-3-one),
17 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-
18 [5a]-androst-3-one),
19 (xxx) methandienone (17[alpha]-methyl-17[beta]-
20 hydroxyandrost-1,4-dien-3-one),
21 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
22 dihydroxyandrost-5-ene),
23 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
24 5[alpha]-androst-1-en-3-one),
25 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
26 dihydroxy-5a-androstane,

- 1 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
2 -5a-androstane,
3 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
4 dihydroxyandrost-4-ene),
5 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
6 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
7 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
8 hydroxyestra-4,9(10)-dien-3-one),
9 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
10 hydroxyestra-4,9-11-trien-3-one),
11 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
12 hydroxyandrost-4-en-3-one),
13 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
14 hydroxyestr-4-en-3-one),
15 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
16 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
17 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
18 1-testosterone'),
19 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
20 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
21 dihydroxyestr-4-ene),
22 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
23 dihydroxyestr-4-ene),
24 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
25 dihydroxyestr-5-ene),
26 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-

1 dihydroxyestr-5-ene),
2 (xlvii) 19-nor-4,9(10)-androstadienedione
3 (estra-4,9(10)-diene-3,17-dione),
4 (xlviii) 19-nor-4-androstenedione (estr-4-
5 en-3,17-dione),
6 (xlix) 19-nor-5-androstenedione (estr-5-
7 en-3,17-dione),
8 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
9 hydroxygon-4-en-3-one),
10 (li) norclostebol (4-chloro-17[beta]-
11 hydroxyestr-4-en-3-one),
12 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
13 hydroxyestr-4-en-3-one),
14 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
15 hydroxyestr-4-en-3-one),
16 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
17 2-oxa-5[alpha]-androstan-3-one),
18 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
19 dihydroxyandrost-4-en-3-one),
20 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
21 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
22 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
23 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
24 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
25 (5[alpha]-androst-1-en-3-one),
26 (lix) testolactone (13-hydroxy-3-oxo-13,17-

1 secoandrosta-1,4-dien-17-oic
2 acid lactone),
3 (lx) testosterone (17[beta]-hydroxyandrost-
4 4-en-3-one),
5 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
6 diethyl-17[beta]-hydroxygon-
7 4,9,11-trien-3-one),
8 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
9 11-trien-3-one).

10 Any person who is otherwise lawfully in possession of an
11 anabolic steroid, or who otherwise lawfully manufactures,
12 distributes, dispenses, delivers, or possesses with intent to
13 deliver an anabolic steroid, which anabolic steroid is
14 expressly intended for and lawfully allowed to be administered
15 through implants to livestock or other nonhuman species, and
16 which is approved by the Secretary of Health and Human
17 Services for such administration, and which the person intends
18 to administer or have administered through such implants,
19 shall not be considered to be in unauthorized possession or to
20 unlawfully manufacture, distribute, dispense, deliver, or
21 possess with intent to deliver such anabolic steroid for
22 purposes of this Act.

23 (d) "Administration" means the Drug Enforcement
24 Administration, United States Department of Justice, or its
25 successor agency.

26 (d-5) "Clinical Director, Prescription Monitoring Program"

1 means a Department of Human Services administrative employee
2 licensed to either prescribe or dispense controlled substances
3 who shall run the clinical aspects of the Department of Human
4 Services Prescription Monitoring Program and its Prescription
5 Information Library.

6 (d-10) "Compounding" means the preparation and mixing of
7 components, excluding flavorings, (1) as the result of a
8 prescriber's prescription drug order or initiative based on
9 the prescriber-patient-pharmacist relationship in the course
10 of professional practice or (2) for the purpose of, or
11 incident to, research, teaching, or chemical analysis and not
12 for sale or dispensing. "Compounding" includes the preparation
13 of drugs or devices in anticipation of receiving prescription
14 drug orders based on routine, regularly observed dispensing
15 patterns. Commercially available products may be compounded
16 for dispensing to individual patients only if both of the
17 following conditions are met: (i) the commercial product is
18 not reasonably available from normal distribution channels in
19 a timely manner to meet the patient's needs and (ii) the
20 prescribing practitioner has requested that the drug be
21 compounded.

22 (e) "Control" means to add a drug or other substance, or
23 immediate precursor, to a Schedule whether by transfer from
24 another Schedule or otherwise.

25 (f) "Controlled Substance" means (i) a drug, substance,
26 immediate precursor, or synthetic drug in the Schedules of

1 Article II of this Act or (ii) a drug or other substance, or
2 immediate precursor, designated as a controlled substance by
3 the Department through administrative rule. The term does not
4 include distilled spirits, wine, malt beverages, or tobacco,
5 as those terms are defined or used in the Liquor Control Act of
6 1934 and the Tobacco Products Tax Act of 1995.

7 (f-5) "Controlled substance analog" means a substance:

8 (1) the chemical structure of which is substantially
9 similar to the chemical structure of a controlled
10 substance in Schedule I or II;

11 (2) which has a stimulant, depressant, or
12 hallucinogenic effect on the central nervous system that
13 is substantially similar to or greater than the stimulant,
14 depressant, or hallucinogenic effect on the central
15 nervous system of a controlled substance in Schedule I or
16 II; or

17 (3) with respect to a particular person, which such
18 person represents or intends to have a stimulant,
19 depressant, or hallucinogenic effect on the central
20 nervous system that is substantially similar to or greater
21 than the stimulant, depressant, or hallucinogenic effect
22 on the central nervous system of a controlled substance in
23 Schedule I or II.

24 (g) "Counterfeit substance" means a controlled substance,
25 which, or the container or labeling of which, without
26 authorization bears the trademark, trade name, or other

1 identifying mark, imprint, number or device, or any likeness
2 thereof, of a manufacturer, distributor, or dispenser other
3 than the person who in fact manufactured, distributed, or
4 dispensed the substance.

5 (h) "Deliver" or "delivery" means the actual, constructive
6 or attempted transfer of possession of a controlled substance,
7 with or without consideration, whether or not there is an
8 agency relationship. "Deliver" or "delivery" does not include
9 the donation of drugs to the extent permitted under the
10 Illinois Drug Reuse Opportunity Program Act.

11 (i) "Department" means the Illinois Department of Human
12 Services (as successor to the Department of Alcoholism and
13 Substance Abuse) or its successor agency.

14 (j) (Blank).

15 (k) "Department of Corrections" means the Department of
16 Corrections of the State of Illinois or its successor agency.

17 (l) "Department of Financial and Professional Regulation"
18 means the Department of Financial and Professional Regulation
19 of the State of Illinois or its successor agency.

20 (m) "Depressant" means any drug that (i) causes an overall
21 depression of central nervous system functions, (ii) causes
22 impaired consciousness and awareness, and (iii) can be
23 habit-forming or lead to a substance abuse problem, including,
24 but not limited to, alcohol, cannabis and its active
25 principles and their analogs, benzodiazepines and their
26 analogs, barbiturates and their analogs, opioids (natural and

1 synthetic) and their analogs, and chloral hydrate and similar
2 sedative hypnotics.

3 (n) (Blank).

4 (o) "Director" means the Director of the Illinois State
5 Police or his or her designated agents.

6 (p) "Dispense" means to deliver a controlled substance to
7 an ultimate user or research subject by or pursuant to the
8 lawful order of a prescriber, including the prescribing,
9 administering, packaging, labeling, or compounding necessary
10 to prepare the substance for that delivery.

11 (q) "Dispenser" means a practitioner who dispenses.

12 (r) "Distribute" means to deliver, other than by
13 administering or dispensing, a controlled substance.

14 (s) "Distributor" means a person who distributes.

15 (t) "Drug" means (1) substances recognized as drugs in the
16 official United States Pharmacopoeia, Official Homeopathic
17 Pharmacopoeia of the United States, or official National
18 Formulary, or any supplement to any of them; (2) substances
19 intended for use in diagnosis, cure, mitigation, treatment, or
20 prevention of disease in man or animals; (3) substances (other
21 than food) intended to affect the structure of any function of
22 the body of man or animals and (4) substances intended for use
23 as a component of any article specified in clause (1), (2), or
24 (3) of this subsection. It does not include devices or their
25 components, parts, or accessories.

26 (t-3) "Electronic health record" or "EHR" means an

1 electronic record of health-related information on an
2 individual that is created, gathered, managed, and consulted
3 by authorized health care clinicians and staff.

4 (t-3.5) "Electronic health record system" or "EHR system"
5 means any computer-based system or combination of federally
6 certified Health IT Modules (defined at 42 CFR 170.102 or its
7 successor) used as a repository for electronic health records
8 and accessed or updated by a prescriber or authorized
9 surrogate in the ordinary course of his or her medical
10 practice. For purposes of connecting to the Prescription
11 Information Library maintained by the Bureau of Pharmacy and
12 Clinical Support Systems or its successor, an EHR system may
13 connect to the Prescription Information Library directly or
14 through all or part of a computer program or system that is a
15 federally certified Health IT Module maintained by a third
16 party and used by the EHR system to secure access to the
17 database.

18 (t-4) "Emergency medical services personnel" has the
19 meaning ascribed to it in the Emergency Medical Services (EMS)
20 Systems Act.

21 (t-5) "Euthanasia agency" means an entity certified by the
22 Department of Financial and Professional Regulation for the
23 purpose of animal euthanasia that holds an animal control
24 facility license or animal shelter license under the Animal
25 Welfare Act. A euthanasia agency is authorized to purchase,
26 store, possess, and utilize Schedule II nonnarcotic and

1 Schedule III nonnarcotic drugs for the sole purpose of animal
2 euthanasia.

3 (t-10) "Euthanasia drugs" means Schedule II or Schedule
4 III substances (nonnarcotic controlled substances) that are
5 used by a euthanasia agency for the purpose of animal
6 euthanasia.

7 (u) "Good faith" means the prescribing or dispensing of a
8 controlled substance by a practitioner in the regular course
9 of professional treatment to or for any person who is under his
10 or her treatment for a pathology or condition other than that
11 individual's physical or psychological dependence upon or
12 addiction to a controlled substance, except as provided
13 herein: and application of the term to a pharmacist shall mean
14 the dispensing of a controlled substance pursuant to the
15 prescriber's order which in the professional judgment of the
16 pharmacist is lawful. The pharmacist shall be guided by
17 accepted professional standards, including, but not limited
18 to, the following, in making the judgment:

19 (1) lack of consistency of prescriber-patient
20 relationship,

21 (2) frequency of prescriptions for same drug by one
22 prescriber for large numbers of patients,

23 (3) quantities beyond those normally prescribed,

24 (4) unusual dosages (recognizing that there may be
25 clinical circumstances where more or less than the usual
26 dose may be used legitimately),

1 (5) unusual geographic distances between patient,
2 pharmacist and prescriber,

3 (6) consistent prescribing of habit-forming drugs.

4 (u-0.5) "Hallucinogen" means a drug that causes markedly
5 altered sensory perception leading to hallucinations of any
6 type.

7 (u-1) "Home infusion services" means services provided by
8 a pharmacy in compounding solutions for direct administration
9 to a patient in a private residence, long-term care facility,
10 or hospice setting by means of parenteral, intravenous,
11 intramuscular, subcutaneous, or intraspinal infusion.

12 (u-5) "Illinois State Police" means the Illinois State
13 Police or its successor agency.

14 (v) "Immediate precursor" means a substance:

15 (1) which the Department has found to be and by rule
16 designated as being a principal compound used, or produced
17 primarily for use, in the manufacture of a controlled
18 substance;

19 (2) which is an immediate chemical intermediary used
20 or likely to be used in the manufacture of such controlled
21 substance; and

22 (3) the control of which is necessary to prevent,
23 curtail or limit the manufacture of such controlled
24 substance.

25 (w) "Instructional activities" means the acts of teaching,
26 educating or instructing by practitioners using controlled

1 substances within educational facilities approved by the State
2 Board of Education or its successor agency.

3 (x) "Local authorities" means a duly organized State,
4 County or Municipal peace unit or police force.

5 (y) "Look-alike substance" means a substance, other than a
6 controlled substance which (1) by overall dosage unit
7 appearance, including shape, color, size, markings or lack
8 thereof, taste, consistency, or any other identifying physical
9 characteristic of the substance, would lead a reasonable
10 person to believe that the substance is a controlled
11 substance, or (2) is expressly or impliedly represented to be
12 a controlled substance or is distributed under circumstances
13 which would lead a reasonable person to believe that the
14 substance is a controlled substance. For the purpose of
15 determining whether the representations made or the
16 circumstances of the distribution would lead a reasonable
17 person to believe the substance to be a controlled substance
18 under this clause (2) of subsection (y), the court or other
19 authority may consider the following factors in addition to
20 any other factor that may be relevant:

21 (a) statements made by the owner or person in control
22 of the substance concerning its nature, use or effect;

23 (b) statements made to the buyer or recipient that the
24 substance may be resold for profit;

25 (c) whether the substance is packaged in a manner
26 normally used for the illegal distribution of controlled

1 substances;

2 (d) whether the distribution or attempted distribution
3 included an exchange of or demand for money or other
4 property as consideration, and whether the amount of the
5 consideration was substantially greater than the
6 reasonable retail market value of the substance.

7 Clause (1) of this subsection (y) shall not apply to a
8 noncontrolled substance in its finished dosage form that was
9 initially introduced into commerce prior to the initial
10 introduction into commerce of a controlled substance in its
11 finished dosage form which it may substantially resemble.

12 Nothing in this subsection (y) prohibits the dispensing or
13 distributing of noncontrolled substances by persons authorized
14 to dispense and distribute controlled substances under this
15 Act, provided that such action would be deemed to be carried
16 out in good faith under subsection (u) if the substances
17 involved were controlled substances.

18 Nothing in this subsection (y) or in this Act prohibits
19 the manufacture, preparation, propagation, compounding,
20 processing, packaging, advertising or distribution of a drug
21 or drugs by any person registered pursuant to Section 510 of
22 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

23 (y-1) "Mail-order pharmacy" means a pharmacy that is
24 located in a state of the United States that delivers,
25 dispenses or distributes, through the United States Postal
26 Service or other common carrier, to Illinois residents, any

1 substance which requires a prescription.

2 (z) "Manufacture" means the production, preparation,
3 propagation, compounding, conversion or processing of a
4 controlled substance other than methamphetamine, either
5 directly or indirectly, by extraction from substances of
6 natural origin, or independently by means of chemical
7 synthesis, or by a combination of extraction and chemical
8 synthesis, and includes any packaging or repackaging of the
9 substance or labeling of its container, except that this term
10 does not include:

11 (1) by an ultimate user, the preparation or
12 compounding of a controlled substance for his or her own
13 use;

14 (2) by a practitioner, or his or her authorized agent
15 under his or her supervision, the preparation,
16 compounding, packaging, or labeling of a controlled
17 substance:

18 (a) as an incident to his or her administering or
19 dispensing of a controlled substance in the course of
20 his or her professional practice; or

21 (b) as an incident to lawful research, teaching or
22 chemical analysis and not for sale; or

23 (3) the packaging, repackaging, or labeling of drugs
24 only to the extent permitted under the Illinois Drug Reuse
25 Opportunity Program Act.

26 (z-1) (Blank).

1 (z-5) "Medication shopping" means the conduct prohibited
2 under subsection (a) of Section 314.5 of this Act.

3 (z-10) "Mid-level practitioner" means (i) a physician
4 assistant who has been delegated authority to prescribe
5 through a written delegation of authority by a physician
6 licensed to practice medicine in all of its branches, in
7 accordance with Section 7.5 of the Physician Assistant
8 Practice Act of 1987, (ii) an advanced practice registered
9 nurse who has been delegated authority to prescribe through a
10 written delegation of authority by a physician licensed to
11 practice medicine in all of its branches or by a podiatric
12 physician, in accordance with Section 65-40 of the Nurse
13 Practice Act, (iii) an advanced practice registered nurse
14 certified as a nurse practitioner, nurse midwife, or clinical
15 nurse specialist who has been granted authority to prescribe
16 by a hospital affiliate in accordance with Section 65-45 of
17 the Nurse Practice Act, (iv) an animal euthanasia agency, or
18 (v) a prescribing psychologist.

19 (aa) "Narcotic drug" means any of the following, whether
20 produced directly or indirectly by extraction from substances
21 of vegetable origin, or independently by means of chemical
22 synthesis, or by a combination of extraction and chemical
23 synthesis:

24 (1) opium, opiates, derivatives of opium and opiates,
25 including their isomers, esters, ethers, salts, and salts
26 of isomers, esters, and ethers, whenever the existence of

1 such isomers, esters, ethers, and salts is possible within
2 the specific chemical designation; however the term
3 "narcotic drug" does not include the isoquinoline
4 alkaloids of opium;

5 (2) (blank);

6 (3) opium poppy and poppy straw;

7 (4) coca leaves, except coca leaves and extracts of
8 coca leaves from which substantially all of the cocaine
9 and ecgonine, and their isomers, derivatives and salts,
10 have been removed;

11 (5) cocaine, its salts, optical and geometric isomers,
12 and salts of isomers;

13 (6) ecgonine, its derivatives, their salts, isomers,
14 and salts of isomers;

15 (7) any compound, mixture, or preparation which
16 contains any quantity of any of the substances referred to
17 in subparagraphs (1) through (6).

18 (bb) "Nurse" means a registered nurse licensed under the
19 Nurse Practice Act.

20 (cc) (Blank).

21 (dd) "Opiate" means any substance having an addiction
22 forming or addiction sustaining liability similar to morphine
23 or being capable of conversion into a drug having addiction
24 forming or addiction sustaining liability.

25 (ee) "Opium poppy" means the plant of the species *Papaver*
26 *somniferum* L., except its seeds.

1 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
2 solution or other liquid form of medication intended for
3 administration by mouth, but the term does not include a form
4 of medication intended for buccal, sublingual, or transmucosal
5 administration.

6 (ff) "Parole and Pardon Board" means the Parole and Pardon
7 Board of the State of Illinois or its successor agency.

8 (gg) "Person" means any individual, corporation,
9 mail-order pharmacy, government or governmental subdivision or
10 agency, business trust, estate, trust, partnership or
11 association, or any other entity.

12 (hh) "Pharmacist" means any person who holds a license or
13 certificate of registration as a registered pharmacist, a
14 local registered pharmacist or a registered assistant
15 pharmacist under the Pharmacy Practice Act.

16 (ii) "Pharmacy" means any store, ship or other place in
17 which pharmacy is authorized to be practiced under the
18 Pharmacy Practice Act.

19 (ii-5) "Pharmacy shopping" means the conduct prohibited
20 under subsection (b) of Section 314.5 of this Act.

21 (ii-10) "Physician" (except when the context otherwise
22 requires) means a person licensed to practice medicine in all
23 of its branches.

24 (jj) "Poppy straw" means all parts, except the seeds, of
25 the opium poppy, after mowing.

26 (kk) "Practitioner" means a physician licensed to practice

1 medicine in all its branches, dentist, optometrist, podiatric
2 physician, veterinarian, scientific investigator, pharmacist,
3 physician assistant, advanced practice registered nurse,
4 licensed practical nurse, registered nurse, emergency medical
5 services personnel, hospital, laboratory, or pharmacy, or
6 other person licensed, registered, or otherwise lawfully
7 permitted by the United States or this State to distribute,
8 dispense, conduct research with respect to, administer or use
9 in teaching or chemical analysis, a controlled substance in
10 the course of professional practice or research.

11 (ll) "Pre-printed prescription" means a written
12 prescription upon which the designated drug has been indicated
13 prior to the time of issuance; the term does not mean a written
14 prescription that is individually generated by machine or
15 computer in the prescriber's office.

16 (mm) "Prescriber" means a physician licensed to practice
17 medicine in all its branches, dentist, optometrist,
18 prescribing psychologist licensed under Section 4.2 of the
19 Clinical Psychologist Licensing Act with prescriptive
20 authority delegated under Section 4.3 of the Clinical
21 Psychologist Licensing Act, podiatric physician, or
22 veterinarian who issues a prescription, a physician assistant
23 who issues a prescription for a controlled substance in
24 accordance with Section 303.05, a written delegation, and a
25 written collaborative agreement required under Section 7.5 of
26 the Physician Assistant Practice Act of 1987, an advanced

1 practice registered nurse with prescriptive authority
2 delegated under Section 65-40 of the Nurse Practice Act and in
3 accordance with Section 303.05, a written delegation, and a
4 written collaborative agreement under Section 65-35 of the
5 Nurse Practice Act, an advanced practice registered nurse
6 certified as a nurse practitioner, nurse midwife, or clinical
7 nurse specialist who has been granted authority to prescribe
8 by a hospital affiliate in accordance with Section 65-45 of
9 the Nurse Practice Act and in accordance with Section 303.05,
10 or an advanced practice registered nurse certified as a nurse
11 practitioner, nurse midwife, or clinical nurse specialist who
12 has full practice authority pursuant to Section 65-43 of the
13 Nurse Practice Act.

14 (nn) "Prescription" means a written, facsimile, or oral
15 order, or an electronic order that complies with applicable
16 federal requirements, of a physician licensed to practice
17 medicine in all its branches, dentist, podiatric physician or
18 veterinarian for any controlled substance, of an optometrist
19 in accordance with Section 15.1 of the Illinois Optometric
20 Practice Act of 1987, of a prescribing psychologist licensed
21 under Section 4.2 of the Clinical Psychologist Licensing Act
22 with prescriptive authority delegated under Section 4.3 of the
23 Clinical Psychologist Licensing Act, of a physician assistant
24 for a controlled substance in accordance with Section 303.05,
25 a written delegation, and a written collaborative agreement
26 required under Section 7.5 of the Physician Assistant Practice

1 Act of 1987, of an advanced practice registered nurse with
2 prescriptive authority delegated under Section 65-40 of the
3 Nurse Practice Act who issues a prescription for a controlled
4 substance in accordance with Section 303.05, a written
5 delegation, and a written collaborative agreement under
6 Section 65-35 of the Nurse Practice Act, of an advanced
7 practice registered nurse certified as a nurse practitioner,
8 nurse midwife, or clinical nurse specialist who has been
9 granted authority to prescribe by a hospital affiliate in
10 accordance with Section 65-45 of the Nurse Practice Act and in
11 accordance with Section 303.05 when required by law, or of an
12 advanced practice registered nurse certified as a nurse
13 practitioner, nurse midwife, or clinical nurse specialist who
14 has full practice authority pursuant to Section 65-43 of the
15 Nurse Practice Act.

16 (nn-5) "Prescription Information Library" (PIL) means an
17 electronic library that contains reported controlled substance
18 data.

19 (nn-10) "Prescription Monitoring Program" (PMP) means the
20 entity that collects, tracks, and stores reported data on
21 controlled substances and select drugs pursuant to Section
22 316.

23 (oo) "Production" or "produce" means manufacture,
24 planting, cultivating, growing, or harvesting of a controlled
25 substance other than methamphetamine.

26 (pp) "Registrant" means every person who is required to

1 register under Section 302 of this Act.

2 (qq) "Registry number" means the number assigned to each
3 person authorized to handle controlled substances under the
4 laws of the United States and of this State.

5 (qq-5) "Secretary" means, as the context requires, either
6 the Secretary of the Department or the Secretary of the
7 Department of Financial and Professional Regulation, and the
8 Secretary's designated agents.

9 (rr) "State" includes the State of Illinois and any state,
10 district, commonwealth, territory, insular possession thereof,
11 and any area subject to the legal authority of the United
12 States of America.

13 (rr-5) "Stimulant" means any drug that (i) causes an
14 overall excitation of central nervous system functions, (ii)
15 causes impaired consciousness and awareness, and (iii) can be
16 habit-forming or lead to a substance abuse problem, including,
17 but not limited to, amphetamines and their analogs,
18 methylphenidate and its analogs, cocaine, and phencyclidine
19 and its analogs.

20 (rr-10) "Synthetic drug" includes, but is not limited to,
21 any synthetic cannabinoids or piperazines or any synthetic
22 cathinones as provided for in Schedule I.

23 (ss) "Ultimate user" means a person who lawfully possesses
24 a controlled substance for his or her own use or for the use of
25 a member of his or her household or for administering to an
26 animal owned by him or her or by a member of his or her

1 household.

2 (Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;
3 102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)

4 (Text of Section after amendment by P.A. 103-881)

5 Sec. 102. Definitions. As used in this Act, unless the
6 context otherwise requires:

7 (a) "Person with a substance use disorder" means any
8 person who has a substance use disorder diagnosis defined as a
9 spectrum of persistent and recurring problematic behavior that
10 encompasses 10 separate classes of drugs: alcohol; caffeine;
11 cannabis; hallucinogens; inhalants; opioids; sedatives,
12 hypnotics and anxiolytics; stimulants; and tobacco; and other
13 unknown substances leading to clinically significant
14 impairment or distress.

15 (b) "Administer" means the direct application of a
16 controlled substance, whether by injection, inhalation,
17 ingestion, or any other means, to the body of a patient,
18 research subject, or animal (as defined by the Humane
19 Euthanasia in Animal Shelters Act) by:

20 (1) a practitioner (or, in his or her presence, by his
21 or her authorized agent),

22 (2) the patient or research subject pursuant to an
23 order, or

24 (3) a euthanasia technician as defined by the Humane
25 Euthanasia in Animal Shelters Act.

1 (c) "Agent" means an authorized person who acts on behalf
2 of or at the direction of a manufacturer, distributor,
3 dispenser, prescriber, or practitioner. It does not include a
4 common or contract carrier, public warehouseman or employee of
5 the carrier or warehouseman.

6 (c-1) "Anabolic Steroids" means any drug or hormonal
7 substance, chemically and pharmacologically related to
8 testosterone (other than estrogens, progestins,
9 corticosteroids, and dehydroepiandrosterone), and includes:

- 10 (i) 3[beta],17-dihydroxy-5a-androstane,
11 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
12 (iii) 5[alpha]-androstane-3,17-dione,
13 (iv) 1-androstenediol (3[beta],
14 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
15 (v) 1-androstenediol (3[alpha],
16 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
17 (vi) 4-androstenediol
18 (3[beta],17[beta]-dihydroxy-androst-4-ene),
19 (vii) 5-androstenediol
20 (3[beta],17[beta]-dihydroxy-androst-5-ene),
21 (viii) 1-androstenedione
22 ([5alpha]-androst-1-en-3,17-dione),
23 (ix) 4-androstenedione
24 (androst-4-en-3,17-dione),
25 (x) 5-androstenedione
26 (androst-5-en-3,17-dione),

- 1 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
2 hydroxyandrost-4-en-3-one),
- 3 (xii) boldenone (17[beta]-hydroxyandrost-
4 1,4,-diene-3-one),
- 5 (xiii) boldione (androsta-1,4-
6 diene-3,17-dione),
- 7 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
8 [beta]-hydroxyandrost-4-en-3-one),
- 9 (xv) clostebol (4-chloro-17[beta]-
10 hydroxyandrost-4-en-3-one),
- 11 (xvi) dehydrochloromethyltestosterone (4-chloro-
12 17[beta]-hydroxy-17[alpha]-methyl-
13 androst-1,4-dien-3-one),
- 14 (xvii) desoxymethyltestosterone
15 (17[alpha]-methyl-5[alpha]
16 -androst-2-en-17[beta]-ol) (a.k.a., madol),
- 17 (xviii) [delta]1-dihydrotestosterone (a.k.a.
18 '1-testosterone') (17[beta]-hydroxy-
19 5[alpha]-androst-1-en-3-one),
- 20 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
21 androstan-3-one),
- 22 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
23 5[alpha]-androstan-3-one),
- 24 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
25 hydroxyestr-4-ene),
- 26 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-

1 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
2 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
3 17[beta]-dihydroxyandrost-1,4-dien-3-one),
4 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
5 hydroxyandrostando[2,3-c]-furazan),
6 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
7 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
8 androst-4-en-3-one),
9 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
10 dihydroxy-estr-4-en-3-one),
11 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
12 hydroxy-5-androstan-3-one),
13 (xxix) mesterolone (1amethyl-17[beta]-hydroxy-
14 [5a]-androstan-3-one),
15 (xxx) methandienone (17[alpha]-methyl-17[beta]-
16 hydroxyandrost-1,4-dien-3-one),
17 (xxxii) methandriol (17[alpha]-methyl-3[beta],17[beta]-
18 dihydroxyandrost-5-ene),
19 (xxxiii) methenolone (1-methyl-17[beta]-hydroxy-
20 5[alpha]-androst-1-en-3-one),
21 (xxxiiii) 17[alpha]-methyl-3[beta], 17[beta]-
22 dihydroxy-5a-androstane,
23 (xxxv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
24 -5a-androstane,
25 (xxxvi) 17[alpha]-methyl-3[beta],17[beta]-
26 dihydroxyandrost-4-ene),

- 1 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
2 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
3 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
4 hydroxyestra-4,9(10)-dien-3-one),
5 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
6 hydroxyestra-4,9-11-trien-3-one),
7 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
8 hydroxyandrost-4-en-3-one),
9 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
10 hydroxyestr-4-en-3-one),
11 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
12 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
13 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
14 1-testosterone'),
15 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
16 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
17 dihydroxyestr-4-ene),
18 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
19 dihydroxyestr-4-ene),
20 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
21 dihydroxyestr-5-ene),
22 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
23 dihydroxyestr-5-ene),
24 (xlvii) 19-nor-4,9(10)-androstadienedione
25 (estra-4,9(10)-diene-3,17-dione),
26 (xlviii) 19-nor-4-androstenedione (estr-4-

1 en-3,17-dione),
2 (xlix) 19-nor-5-androstenedione (estr-5-
3 en-3,17-dione),
4 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
5 hydroxygon-4-en-3-one),
6 (li) norclostebol (4-chloro-17[beta]-
7 hydroxyestr-4-en-3-one),
8 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
9 hydroxyestr-4-en-3-one),
10 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
11 hydroxyestr-4-en-3-one),
12 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
13 2-oxa-5[alpha]-androstan-3-one),
14 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
15 dihydroxyandrost-4-en-3-one),
16 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
17 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
18 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
19 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
20 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
21 (5[alpha]-androst-1-en-3-one),
22 (lix) testolactone (13-hydroxy-3-oxo-13,17-
23 secoandrosta-1,4-dien-17-oic
24 acid lactone),
25 (lx) testosterone (17[beta]-hydroxyandrost-
26 4-en-3-one),

1 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
2 diethyl-17[beta]-hydroxygon-
3 4,9,11-trien-3-one),
4 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
5 11-trien-3-one).

6 Any person who is otherwise lawfully in possession of an
7 anabolic steroid, or who otherwise lawfully manufactures,
8 distributes, dispenses, delivers, or possesses with intent to
9 deliver an anabolic steroid, which anabolic steroid is
10 expressly intended for and lawfully allowed to be administered
11 through implants to livestock or other nonhuman species, and
12 which is approved by the Secretary of Health and Human
13 Services for such administration, and which the person intends
14 to administer or have administered through such implants,
15 shall not be considered to be in unauthorized possession or to
16 unlawfully manufacture, distribute, dispense, deliver, or
17 possess with intent to deliver such anabolic steroid for
18 purposes of this Act.

19 (d) "Administration" means the Drug Enforcement
20 Administration, United States Department of Justice, or its
21 successor agency.

22 (d-5) "Clinical Director, Prescription Monitoring Program"
23 means a Department of Human Services administrative employee
24 licensed to either prescribe or dispense controlled substances
25 who shall run the clinical aspects of the Department of Human
26 Services Prescription Monitoring Program and its Prescription

1 Information Library.

2 (d-10) "Compounding" means the preparation and mixing of
3 components, excluding flavorings, (1) as the result of a
4 prescriber's prescription drug order or initiative based on
5 the prescriber-patient-pharmacist relationship in the course
6 of professional practice or (2) for the purpose of, or
7 incident to, research, teaching, or chemical analysis and not
8 for sale or dispensing. "Compounding" includes the preparation
9 of drugs or devices in anticipation of receiving prescription
10 drug orders based on routine, regularly observed dispensing
11 patterns. Commercially available products may be compounded
12 for dispensing to individual patients only if both of the
13 following conditions are met: (i) the commercial product is
14 not reasonably available from normal distribution channels in
15 a timely manner to meet the patient's needs and (ii) the
16 prescribing practitioner has requested that the drug be
17 compounded.

18 (e) "Control" means to add a drug or other substance, or
19 immediate precursor, to a Schedule whether by transfer from
20 another Schedule or otherwise.

21 (f) "Controlled Substance" means (i) a drug, substance,
22 immediate precursor, or synthetic drug in the Schedules of
23 Article II of this Act or (ii) a drug or other substance, or
24 immediate precursor, designated as a controlled substance by
25 the Department through administrative rule. The term does not
26 include distilled spirits, wine, malt beverages, or tobacco,

1 as those terms are defined or used in the Liquor Control Act of
2 1934 and the Tobacco Products Tax Act of 1995.

3 (f-5) "Controlled substance analog" means a substance:

4 (1) the chemical structure of which is substantially
5 similar to the chemical structure of a controlled
6 substance in Schedule I or II;

7 (2) which has a stimulant, depressant, or
8 hallucinogenic effect on the central nervous system that
9 is substantially similar to or greater than the stimulant,
10 depressant, or hallucinogenic effect on the central
11 nervous system of a controlled substance in Schedule I or
12 II; or

13 (3) with respect to a particular person, which such
14 person represents or intends to have a stimulant,
15 depressant, or hallucinogenic effect on the central
16 nervous system that is substantially similar to or greater
17 than the stimulant, depressant, or hallucinogenic effect
18 on the central nervous system of a controlled substance in
19 Schedule I or II.

20 (g) "Counterfeit substance" means a controlled substance,
21 which, or the container or labeling of which, without
22 authorization bears the trademark, trade name, or other
23 identifying mark, imprint, number or device, or any likeness
24 thereof, of a manufacturer, distributor, or dispenser other
25 than the person who in fact manufactured, distributed, or
26 dispensed the substance.

1 (h) "Deliver" or "delivery" means the actual, constructive
2 or attempted transfer of possession of a controlled substance,
3 with or without consideration, whether or not there is an
4 agency relationship. "Deliver" or "delivery" does not include
5 the donation of drugs to the extent permitted under the
6 Illinois Drug Reuse Opportunity Program Act.

7 (i) "Department" means the Illinois Department of Human
8 Services (as successor to the Department of Alcoholism and
9 Substance Abuse) or its successor agency.

10 (j) (Blank).

11 (k) "Department of Corrections" means the Department of
12 Corrections of the State of Illinois or its successor agency.

13 (l) "Department of Financial and Professional Regulation"
14 means the Department of Financial and Professional Regulation
15 of the State of Illinois or its successor agency.

16 (m) "Depressant" means any drug that (i) causes an overall
17 depression of central nervous system functions, (ii) causes
18 impaired consciousness and awareness, and (iii) can be
19 habit-forming or lead to a substance misuse or substance use
20 disorder, including, but not limited to, alcohol, cannabis and
21 its active principles and their analogs, benzodiazepines and
22 their analogs, barbiturates and their analogs, opioids
23 (natural and synthetic) and their analogs, and chloral hydrate
24 and similar sedative hypnotics.

25 (n) (Blank).

26 (o) "Director" means the Director of the Illinois State

1 Police or his or her designated agents.

2 (p) "Dispense" means to deliver a controlled substance to
3 an ultimate user or research subject by or pursuant to the
4 lawful order of a prescriber, including the prescribing,
5 administering, packaging, labeling, or compounding necessary
6 to prepare the substance for that delivery.

7 (q) "Dispenser" means a practitioner who dispenses.

8 (r) "Distribute" means to deliver, other than by
9 administering or dispensing, a controlled substance.

10 (s) "Distributor" means a person who distributes.

11 (t) "Drug" means (1) substances recognized as drugs in the
12 official United States Pharmacopoeia, Official Homeopathic
13 Pharmacopoeia of the United States, or official National
14 Formulary, or any supplement to any of them; (2) substances
15 intended for use in diagnosis, cure, mitigation, treatment, or
16 prevention of disease in man or animals; (3) substances (other
17 than food) intended to affect the structure of any function of
18 the body of man or animals and (4) substances intended for use
19 as a component of any article specified in clause (1), (2), or
20 (3) of this subsection. It does not include devices or their
21 components, parts, or accessories.

22 (t-3) "Electronic health record" or "EHR" means an
23 electronic record of health-related information on an
24 individual that is created, gathered, managed, and consulted
25 by authorized health care clinicians and staff.

26 (t-3.5) "Electronic health record system" or "EHR system"

1 means any computer-based system or combination of federally
2 certified Health IT Modules (defined at 42 CFR 170.102 or its
3 successor) used as a repository for electronic health records
4 and accessed or updated by a prescriber or authorized
5 surrogate in the ordinary course of his or her medical
6 practice. For purposes of connecting to the Prescription
7 Information Library maintained by the Bureau of Pharmacy and
8 Clinical Support Systems or its successor, an EHR system may
9 connect to the Prescription Information Library directly or
10 through all or part of a computer program or system that is a
11 federally certified Health IT Module maintained by a third
12 party and used by the EHR system to secure access to the
13 database.

14 (t-4) "Emergency medical services personnel" has the
15 meaning ascribed to it in the Emergency Medical Services (EMS)
16 Systems Act.

17 (t-5) "Euthanasia agency" means an entity certified by the
18 Department of Financial and Professional Regulation for the
19 purpose of animal euthanasia that holds an animal control
20 facility license or animal shelter license under the Animal
21 Welfare Act. A euthanasia agency is authorized to purchase,
22 store, possess, and utilize Schedule II nonnarcotic and
23 Schedule III nonnarcotic drugs for the sole purpose of animal
24 euthanasia.

25 (t-10) "Euthanasia drugs" means Schedule II or Schedule
26 III substances (nonnarcotic controlled substances) that are

1 used by a euthanasia agency for the purpose of animal
2 euthanasia.

3 (u) "Good faith" means the prescribing or dispensing of a
4 controlled substance by a practitioner in the regular course
5 of professional treatment to or for any person who is under his
6 or her treatment for a pathology or condition other than that
7 individual's physical or psychological dependence upon a
8 controlled substance, except as provided herein: and
9 application of the term to a pharmacist shall mean the
10 dispensing of a controlled substance pursuant to the
11 prescriber's order which in the professional judgment of the
12 pharmacist is lawful. The pharmacist shall be guided by
13 accepted professional standards, including, but not limited
14 to, the following, in making the judgment:

15 (1) lack of consistency of prescriber-patient
16 relationship,

17 (2) frequency of prescriptions for same drug by one
18 prescriber for large numbers of patients,

19 (3) quantities beyond those normally prescribed,

20 (4) unusual dosages (recognizing that there may be
21 clinical circumstances where more or less than the usual
22 dose may be used legitimately),

23 (5) unusual geographic distances between patient,
24 pharmacist and prescriber,

25 (6) consistent prescribing of habit-forming drugs.

26 (u-0.5) "Hallucinogen" means a drug that causes markedly

1 altered sensory perception leading to hallucinations of any
2 type.

3 (u-1) "Home infusion services" means services provided by
4 a pharmacy in compounding solutions for direct administration
5 to a patient in a private residence, long-term care facility,
6 or hospice setting by means of parenteral, intravenous,
7 intramuscular, subcutaneous, or intraspinal infusion.

8 (u-5) "Illinois State Police" means the Illinois State
9 Police or its successor agency.

10 (v) "Immediate precursor" means a substance:

11 (1) which the Department has found to be and by rule
12 designated as being a principal compound used, or produced
13 primarily for use, in the manufacture of a controlled
14 substance;

15 (2) which is an immediate chemical intermediary used
16 or likely to be used in the manufacture of such controlled
17 substance; and

18 (3) the control of which is necessary to prevent,
19 curtail or limit the manufacture of such controlled
20 substance.

21 (w) "Instructional activities" means the acts of teaching,
22 educating or instructing by practitioners using controlled
23 substances within educational facilities approved by the State
24 Board of Education or its successor agency.

25 (w-1) "Isomer" means optical isomer, unless specifically
26 detailed in this Act.

1 (x) "Local authorities" means a duly organized State,
2 County or Municipal peace unit or police force.

3 (y) "Look-alike substance" means a substance, other than a
4 controlled substance which (1) by overall dosage unit
5 appearance, including shape, color, size, markings or lack
6 thereof, taste, consistency, or any other identifying physical
7 characteristic of the substance, would lead a reasonable
8 person to believe that the substance is a controlled
9 substance, or (2) is expressly or impliedly represented to be
10 a controlled substance or is distributed under circumstances
11 which would lead a reasonable person to believe that the
12 substance is a controlled substance. For the purpose of
13 determining whether the representations made or the
14 circumstances of the distribution would lead a reasonable
15 person to believe the substance to be a controlled substance
16 under this clause (2) of subsection (y), the court or other
17 authority may consider the following factors in addition to
18 any other factor that may be relevant:

19 (a) statements made by the owner or person in control
20 of the substance concerning its nature, use or effect;

21 (b) statements made to the buyer or recipient that the
22 substance may be resold for profit;

23 (c) whether the substance is packaged in a manner
24 normally used for the illegal distribution of controlled
25 substances;

26 (d) whether the distribution or attempted distribution

1 included an exchange of or demand for money or other
2 property as consideration, and whether the amount of the
3 consideration was substantially greater than the
4 reasonable retail market value of the substance.

5 Clause (1) of this subsection (y) shall not apply to a
6 noncontrolled substance in its finished dosage form that was
7 initially introduced into commerce prior to the initial
8 introduction into commerce of a controlled substance in its
9 finished dosage form which it may substantially resemble.

10 Nothing in this subsection (y) prohibits the dispensing or
11 distributing of noncontrolled substances by persons authorized
12 to dispense and distribute controlled substances under this
13 Act, provided that such action would be deemed to be carried
14 out in good faith under subsection (u) if the substances
15 involved were controlled substances.

16 Nothing in this subsection (y) or in this Act prohibits
17 the manufacture, preparation, propagation, compounding,
18 processing, packaging, advertising or distribution of a drug
19 or drugs by any person registered pursuant to Section 510 of
20 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

21 (y-1) "Mail-order pharmacy" means a pharmacy that is
22 located in a state of the United States that delivers,
23 dispenses or distributes, through the United States Postal
24 Service or other common carrier, to Illinois residents, any
25 substance which requires a prescription.

26 (z) "Manufacture" means the production, preparation,

1 propagation, compounding, conversion or processing of a
2 controlled substance other than methamphetamine, either
3 directly or indirectly, by extraction from substances of
4 natural origin, or independently by means of chemical
5 synthesis, or by a combination of extraction and chemical
6 synthesis, and includes any packaging or repackaging of the
7 substance or labeling of its container, except that this term
8 does not include:

9 (1) by an ultimate user, the preparation or
10 compounding of a controlled substance for his or her own
11 use;

12 (2) by a practitioner, or his or her authorized agent
13 under his or her supervision, the preparation,
14 compounding, packaging, or labeling of a controlled
15 substance:

16 (a) as an incident to his or her administering or
17 dispensing of a controlled substance in the course of
18 his or her professional practice; or

19 (b) as an incident to lawful research, teaching or
20 chemical analysis and not for sale; or

21 (3) the packaging, repackaging, or labeling of drugs
22 only to the extent permitted under the Illinois Drug Reuse
23 Opportunity Program Act.

24 (z-1) (Blank).

25 (z-5) "Medication shopping" means the conduct prohibited
26 under subsection (a) of Section 314.5 of this Act.

1 (z-10) "Mid-level practitioner" means (i) a physician
2 assistant who has been delegated authority to prescribe
3 through a written delegation of authority by a physician
4 licensed to practice medicine in all of its branches, in
5 accordance with Section 7.5 of the Physician Assistant
6 Practice Act of 1987, (ii) an advanced practice registered
7 nurse who has been delegated authority to prescribe through a
8 written delegation of authority by a physician licensed to
9 practice medicine in all of its branches or by a podiatric
10 physician, in accordance with Section 65-40 of the Nurse
11 Practice Act, (iii) an advanced practice registered nurse
12 certified as a nurse practitioner, nurse midwife, or clinical
13 nurse specialist who has been granted authority to prescribe
14 by a hospital affiliate in accordance with Section 65-45 of
15 the Nurse Practice Act, (iv) an animal euthanasia agency, or
16 (v) a prescribing psychologist.

17 (aa) "Narcotic drug" means any of the following, whether
18 produced directly or indirectly by extraction from substances
19 of vegetable origin, or independently by means of chemical
20 synthesis, or by a combination of extraction and chemical
21 synthesis:

22 (1) opium, opiates, derivatives of opium and opiates,
23 including their isomers, esters, ethers, salts, and salts
24 of isomers, esters, and ethers, whenever the existence of
25 such isomers, esters, ethers, and salts is possible within
26 the specific chemical designation; however the term

1 "narcotic drug" does not include the isoquinoline
2 alkaloids of opium;

3 (2) (blank);

4 (3) opium poppy and poppy straw;

5 (4) coca leaves, except coca leaves and extracts of
6 coca leaves from which substantially all of the cocaine
7 and ecgonine, and their isomers, derivatives and salts,
8 have been removed;

9 (5) cocaine, its salts, optical and geometric isomers,
10 and salts of isomers;

11 (6) ecgonine, its derivatives, their salts, isomers,
12 and salts of isomers;

13 (7) any compound, mixture, or preparation which
14 contains any quantity of any of the substances referred to
15 in subparagraphs (1) through (6).

16 (bb) "Nurse" means a registered nurse licensed under the
17 Nurse Practice Act.

18 (cc) (Blank).

19 (dd) "Opiate" means a drug derived from or related to
20 opium.

21 (ee) "Opium poppy" means the plant of the species *Papaver*
22 *somniferum* L., except its seeds.

23 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
24 solution or other liquid form of medication intended for
25 administration by mouth, but the term does not include a form
26 of medication intended for buccal, sublingual, or transmucosal

1 administration.

2 (ff) "Parole and Pardon Board" means the Parole and Pardon
3 Board of the State of Illinois or its successor agency.

4 (gg) "Person" means any individual, corporation,
5 mail-order pharmacy, government or governmental subdivision or
6 agency, business trust, estate, trust, partnership or
7 association, or any other entity.

8 (hh) "Pharmacist" means any person who holds a license or
9 certificate of registration as a registered pharmacist, a
10 local registered pharmacist or a registered assistant
11 pharmacist under the Pharmacy Practice Act.

12 (ii) "Pharmacy" means any store, ship or other place in
13 which pharmacy is authorized to be practiced under the
14 Pharmacy Practice Act.

15 (ii-5) "Pharmacy shopping" means the conduct prohibited
16 under subsection (b) of Section 314.5 of this Act.

17 (ii-10) "Physician" (except when the context otherwise
18 requires) means a person licensed to practice medicine in all
19 of its branches.

20 (jj) "Poppy straw" means all parts, except the seeds, of
21 the opium poppy, after mowing.

22 (kk) "Practitioner" means a physician licensed to practice
23 medicine in all its branches, dentist, optometrist, podiatric
24 physician, veterinarian, scientific investigator, pharmacist,
25 physician assistant, advanced practice registered nurse,
26 licensed practical nurse, registered nurse, emergency medical

1 services personnel, hospital, laboratory, or pharmacy, or
2 other person licensed, registered, or otherwise lawfully
3 permitted by the United States or this State to distribute,
4 dispense, conduct research with respect to, administer or use
5 in teaching or chemical analysis, a controlled substance in
6 the course of professional practice or research.

7 (ll) "Pre-printed prescription" means a written
8 prescription upon which the designated drug has been indicated
9 prior to the time of issuance; the term does not mean a written
10 prescription that is individually generated by machine or
11 computer in the prescriber's office.

12 (mm) "Prescriber" means a physician licensed to practice
13 medicine in all its branches, dentist, optometrist,
14 prescribing psychologist licensed under Section 4.2 of the
15 Clinical Psychologist Licensing Act with prescriptive
16 authority delegated under Section 4.3 of the Clinical
17 Psychologist Licensing Act, podiatric physician, or
18 veterinarian who issues a prescription, a physician assistant
19 who issues a prescription for a controlled substance in
20 accordance with Section 303.05, a written delegation, and a
21 written collaborative agreement required under Section 7.5 of
22 the Physician Assistant Practice Act of 1987, an advanced
23 practice registered nurse with prescriptive authority
24 delegated under Section 65-40 of the Nurse Practice Act and in
25 accordance with Section 303.05, a written delegation, and a
26 written collaborative agreement under Section 65-35 of the

1 Nurse Practice Act, an advanced practice registered nurse
2 certified as a nurse practitioner, nurse midwife, or clinical
3 nurse specialist who has been granted authority to prescribe
4 by a hospital affiliate in accordance with Section 65-45 of
5 the Nurse Practice Act and in accordance with Section 303.05,
6 or an advanced practice registered nurse certified as a nurse
7 practitioner, nurse midwife, or clinical nurse specialist who
8 has full practice authority pursuant to Section 65-43 of the
9 Nurse Practice Act.

10 (nn) "Prescription" means a written, facsimile, or oral
11 order, or an electronic order that complies with applicable
12 federal requirements, of a physician licensed to practice
13 medicine in all its branches, dentist, podiatric physician or
14 veterinarian for any controlled substance, of an optometrist
15 in accordance with Section 15.1 of the Illinois Optometric
16 Practice Act of 1987, of a prescribing psychologist licensed
17 under Section 4.2 of the Clinical Psychologist Licensing Act
18 with prescriptive authority delegated under Section 4.3 of the
19 Clinical Psychologist Licensing Act, of a physician assistant
20 for a controlled substance in accordance with Section 303.05,
21 a written delegation, and a written collaborative agreement
22 required under Section 7.5 of the Physician Assistant Practice
23 Act of 1987, of an advanced practice registered nurse with
24 prescriptive authority delegated under Section 65-40 of the
25 Nurse Practice Act who issues a prescription for a controlled
26 substance in accordance with Section 303.05, a written

1 delegation, and a written collaborative agreement under
2 Section 65-35 of the Nurse Practice Act, of an advanced
3 practice registered nurse certified as a nurse practitioner,
4 nurse midwife, or clinical nurse specialist who has been
5 granted authority to prescribe by a hospital affiliate in
6 accordance with Section 65-45 of the Nurse Practice Act and in
7 accordance with Section 303.05 when required by law, or of an
8 advanced practice registered nurse certified as a nurse
9 practitioner, nurse midwife, or clinical nurse specialist who
10 has full practice authority pursuant to Section 65-43 of the
11 Nurse Practice Act.

12 (nn-5) "Prescription Information Library" (PIL) means an
13 electronic library that contains reported controlled substance
14 data.

15 (nn-10) "Prescription Monitoring Program" (PMP) means the
16 entity that collects, tracks, and stores reported data on
17 controlled substances and select drugs pursuant to Section
18 316.

19 (oo) "Production" or "produce" means manufacture,
20 planting, cultivating, growing, or harvesting of a controlled
21 substance other than methamphetamine.

22 (pp) "Registrant" means every person who is required to
23 register under Section 302 of this Act.

24 (qq) "Registry number" means the number assigned to each
25 person authorized to handle controlled substances under the
26 laws of the United States and of this State.

1 (qq-5) "Secretary" means, as the context requires, either
2 the Secretary of the Department or the Secretary of the
3 Department of Financial and Professional Regulation, and the
4 Secretary's designated agents.

5 (rr) "State" includes the State of Illinois and any state,
6 district, commonwealth, territory, insular possession thereof,
7 and any area subject to the legal authority of the United
8 States of America.

9 (rr-5) "Stimulant" means any drug that (i) causes an
10 overall excitation of central nervous system functions, (ii)
11 causes impaired consciousness and awareness, and (iii) can be
12 habit-forming or lead to a substance use disorder, including,
13 but not limited to, amphetamines and their analogs,
14 methylphenidate and its analogs, cocaine, and phencyclidine
15 and its analogs.

16 (rr-10) "Synthetic drug" includes, but is not limited to,
17 any synthetic cannabinoids or piperazines or any synthetic
18 cathinones as provided for in Schedule I.

19 (ss) "Ultimate user" means a person who lawfully possesses
20 a controlled substance for his or her own use or for the use of
21 a member of his or her household or for administering to an
22 animal owned by him or her or by a member of his or her
23 household.

24 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
25 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

1 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

2 Sec. 204. (a) The controlled substances listed in this
3 Section are included in Schedule I.

4 (b) Unless specifically excepted or unless listed in
5 another schedule, any of the following opiates, including
6 their isomers, esters, ethers, salts, and salts of isomers,
7 esters, and ethers, whenever the existence of such isomers,
8 esters, ethers and salts is possible within the specific
9 chemical designation:

10 (1) Acetylmethadol;

11 (1.1) (Blank); ~~Acetyl-alpha-methylfentanyl~~

12 ~~(N-[1-(1-methyl-2-phenethyl)-~~

13 ~~4-piperidinyl]-N-phenylacetamide);~~

14 (2) Allylprodine;

15 (3) Alphacetylmethadol, except
16 levo-alphacetylmethadol (also known as levo-alpha-
17 acetylmethadol, levomethadyl acetate, or LAAM);

18 (4) Alphameprodine;

19 (5) Alphamethadol;

20 (6) Alpha-methylfentanyl

21 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

22 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

23 propanilido) piperidine;

24 (6.1) (Blank); ~~Alpha-methylthiofentanyl~~

25 ~~(N-[1-methyl-2-(2-thienyl)ethyl-~~

26 ~~4-piperidinyl]-N-phenylpropanamide);~~

- 1 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 2 (7.1) PEPAP
- 3 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 4 (8) Benzethidine;
- 5 (9) Betacetylmethadol;
- 6 (9.1) (Blank); ~~Beta-hydroxyfentanyl~~
- 7 ~~(N-[1-(2-hydroxy-2-phenethyl)-~~
- 8 ~~4-piperidinyl]-N-phenylpropanamide);~~
- 9 (10) Betameprodine;
- 10 (11) Betamethadol;
- 11 (12) Betaprodine;
- 12 (12.1) Brorphine;
- 13 (13) Clonitazene;
- 14 (14) Dextromoramide;
- 15 (15) Diampromide;
- 16 (16) Diethylthiambutene;
- 17 (17) Difenoquin;
- 18 (18) Dimenoxadol;
- 19 (19) Dimepheptanol;
- 20 (20) Dimethylthiambutene;
- 21 (21) Dioxaphetylbutyrate;
- 22 (22) Dipipanone;
- 23 (23) Ethylmethylthiambutene;
- 24 (24) Etonitazene;
- 25 (25) Etoxadine;
- 26 (25.1) Flunitazene;

- 1 (26) Furethidine;
- 2 (27) Hydroxypethidine;
- 3 (27.1) Isotonitazene;
- 4 (28) Ketobemidone;
- 5 (29) Levomoramide;
- 6 (30) Levophenacymorphan;
- 7 (31) (Blank); ~~3-Methylfentanyl~~
- 8 ~~(N-[3-methyl-1-(2-phenylethyl)-~~
- 9 ~~4-piperidyl]-N-phenylpropanamide);~~
- 10 (31.1) (Blank); ~~3-Methylthiofentanyl~~
- 11 ~~(N-[3-methyl-1-(2-thienyl)ethyl-~~
- 12 ~~4-piperidinyl]-N-phenylpropanamide);~~
- 13 (31.2) Metonitazene;
- 14 (32) Morpheridine;
- 15 (33) Noracymethadol;
- 16 (34) Norlevorphanol;
- 17 (35) Normethadone;
- 18 (36) Norpipanone;
- 19 (36.1) (Blank); ~~Para-fluorofentanyl~~
- 20 ~~(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-~~
- 21 ~~4-piperidinyl]propanamide);~~
- 22 (37) Phenadoxone;
- 23 (38) Phenampromide;
- 24 (39) Phenomorphan;
- 25 (40) Phenoperidine;
- 26 (41) Piritramide;

- 1 (42) Proheptazine;
- 2 (43) Properidine;
- 3 (44) Propiram;
- 4 (45) Racemoramide;
- 5 (45.1) (Blank); ~~Thiofentanyl~~
- 6 ~~(N-phenyl-N-[1-(2-thienyl)ethyl-~~
- 7 ~~4-piperidinyl]-propanamide);~~
- 8 (46) Tilidine;
- 9 (47) Trimeperidine;
- 10 (48) (Blank); ~~Beta-hydroxy-3-methylfentanyl (other~~
- 11 ~~name:~~
- 12 ~~N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-~~
- 13 ~~N-phenylpropanamide);~~
- 14 (49) (Blank); ~~Furanyl-fentanyl (FU-F);~~
- 15 (50) (Blank); ~~Butyryl-fentanyl;~~
- 16 (51) (Blank); ~~Valeryl-fentanyl;~~
- 17 (52) (Blank); ~~Acetyl-fentanyl;~~
- 18 (53) (Blank); ~~Beta-hydroxy-thiofentanyl;~~
- 19 (54) 3,4-dichloro-N-[2-
- 20 (dimethylamino)cyclohexyl]-N-
- 21 methylbenzamide (U-47700);
- 22 (55) 4-chloro-N-[1-[2-
- 23 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
- 24 benzenesulfonamide (W-18);
- 25 (56) 4-chloro-N-[1-(2-phenylethyl)
- 26 -2-piperidinylidene]-benzenesulfonamide (W-15);

1 (57) (Blank). ~~acrylfentanyl (acryloylfentanyl)~~.

2 (c) Unless specifically excepted or unless listed in
3 another schedule, any of the following opium derivatives, its
4 salts, isomers and salts of isomers, whenever the existence of
5 such salts, isomers and salts of isomers is possible within
6 the specific chemical designation:

7 (1) Acetorphine;

8 (2) Acetyldihydrocodeine;

9 (3) Benzylmorphine;

10 (4) Codeine methylbromide;

11 (5) Codeine-N-Oxide;

12 (6) Cyprenorphine;

13 (7) Desomorphine;

14 (8) Diacetyldihydromorphine (Dihydroheroin);

15 (9) Dihydromorphine;

16 (10) Drotebanol;

17 (11) Etorphine (except hydrochloride salt);

18 (12) Heroin;

19 (13) Hydromorphenol;

20 (14) Methyldesorphine;

21 (15) Methyldihydromorphine;

22 (16) Morphine methylbromide;

23 (17) Morphine methylsulfonate;

24 (18) Morphine-N-Oxide;

25 (19) Myrophine;

26 (20) Nicocodeine;

1 (21) Nicomorphine;

2 (22) Normorphine;

3 (23) Pholcodine;

4 (24) Thebacon.

5 (d) Unless specifically excepted or unless listed in
6 another schedule, any material, compound, mixture, or
7 preparation which contains any quantity of the following
8 hallucinogenic substances, or which contains any of its salts,
9 isomers and salts of isomers, whenever the existence of such
10 salts, isomers, and salts of isomers is possible within the
11 specific chemical designation (for the purposes of this
12 paragraph only, the term "isomer" includes the optical,
13 position and geometric isomers):

14 (1) 3,4-methylenedioxyamphetamine

15 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
16 methylenedioxyamphetamine, MDA);

17 (1.1) Alpha-ethyltryptamine

18 (some trade or other names: etryptamine;

19 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

20 3-(2-aminobutyl)indole; a-ET; and AET);

21 (2) 3,4-methylenedioxymethamphetamine (MDMA);

22 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

23 (also known as: N-ethyl-alpha-methyl-

24 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

25 and MDEA);

26 (2.2) (Blank); ~~N-Benzylpiperazine (BZP);~~

- 1 (2.2-1) (Blank); ~~Trifluoromethylphenylpiperazine~~
2 ~~(TFMPP)~~;
- 3 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MDMA);
4 (4) 3,4,5-trimethoxyamphetamine (TMA);
5 (5) (Blank);
6 (6) Diethyltryptamine (DET);
7 (7) Dimethyltryptamine (DMT);
8 (7.1) 5-Methoxy-diallyltryptamine;
9 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
10 (9) Ibogaine (some trade and other names:
11 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
12 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
13 indole; Tabernanthe iboga);
14 (10) Lysergic acid diethylamide;
15 (10.1) Salvinorin A;
16 (10.5) Salvia divinorum (meaning all parts of the
17 plant presently classified botanically as Salvia
18 divinorum, whether growing or not, the seeds thereof, any
19 extract from any part of that plant, and every compound,
20 manufacture, salts, isomers, and salts of isomers whenever
21 the existence of such salts, isomers, and salts of isomers
22 is possible within the specific chemical designation,
23 derivative, mixture, or preparation of that plant, its
24 seeds or extracts);
25 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
26 (12) Peyote (meaning all parts of the plant presently

1 classified botanically as *Lophophora williamsii* Lemaire,
2 whether growing or not, the seeds thereof, any extract
3 from any part of that plant, and every compound,
4 manufacture, salts, derivative, mixture, or preparation of
5 that plant, its seeds or extracts);

6 (13) N-ethyl-3-piperidyl benzilate (JB 318);

7 (14) N-methyl-3-piperidyl benzilate;

8 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

9 (also known as N-hydroxy-alpha-methyl-

10 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

11 (15) Parahexyl; some trade or other names:

12 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
13 dibenzo (b,d) pyran; Synhexyl;

14 (16) Psilocybin;

15 (17) Psilocyn;

16 (18) Alpha-methyltryptamine (AMT);

17 (19) 2,5-dimethoxyamphetamine

18 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

19 (20) 4-bromo-2,5-dimethoxyamphetamine

20 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

21 4-bromo-2,5-DMA);

22 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

23 Some trade or other names: 2-(4-bromo-

24 2,5-dimethoxyphenyl)-1-aminoethane;

25 alpha-desmethyl DOB, 2CB, Nexus;

26 (21) 4-methoxyamphetamine

1 (4-methoxy-alpha-methylphenethylamine;
2 paramethoxyamphetamine; PMA);
3 (22) (Blank);
4 (23) Ethylamine analog of phencyclidine.
5 Some trade or other names:
6 N-ethyl-1-phenylcyclohexylamine,
7 (1-phenylcyclohexyl) ethylamine,
8 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
9 (24) Pyrrolidine analog of phencyclidine. Some trade
10 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
11 PHP;
12 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
13 (26) 2,5-dimethoxy-4-ethylamphetamine
14 (another name: DOET);
15 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
16 (another name: TCPy);
17 (28) (Blank);
18 (29) Thiophene analog of phencyclidine (some trade
19 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
20 2-thienyl analog of phencyclidine; TPCP; TCP);
21 (29.1) Benzothiophene analog of phencyclidine. Some
22 trade or other names: BTCP or benocyclidine;
23 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
24 (30) Bufotenine (some trade or other names:
25 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
26 3-(2-dimethylaminoethyl)-5-indolol;

- 1 5-hydroxy-N,N-dimethyltryptamine;
2 N,N-dimethylserotonin; mappine);
3 (31) (Blank);
4 (32) (Blank);
5 (33) (Blank);
6 (34) (Blank);
7 (34.5) (Blank);
8 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
9 (2-methyloctan-2-yl)-6a,7,
10 10,10a-tetrahydrobenzo[c]chromen-1-ol
11 Some trade or other names: HU-210;
12 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
13 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
14 tetrahydrobenzo[c]chromen-1-ol, its isomers,
15 salts, and salts of isomers; Some trade or other
16 names: HU-210, Dexanabinol;
17 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
18 6,6-dimethyl-3-(2-methyloctan-2-yl)-
19 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
20 Some trade or other names: HU-211;
21 (37) (Blank);
22 (38) (Blank);
23 (39) (Blank);
24 (40) (Blank);
25 (41) (Blank);
26 (42) (Blank); ~~Any compound structurally derived from~~

1 ~~3-(1-naphthoyl)indole or~~
2 ~~1H-indol-3-yl-(1-naphthyl)methane by substitution at the~~
3 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
4 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
5 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
6 ~~2-(4-morpholinyl)ethyl whether or not further substituted~~
7 ~~in the indole ring to any extent, whether or not~~
8 ~~substituted in the naphthyl ring to any extent. Examples~~
9 ~~of this structural class include, but are not limited to,~~
10 ~~JWH 018, AM 2201, JWH 175, JWH 184, and JWH 185;~~

11 (43) (Blank); ~~Any compound structurally derived from~~
12 ~~3-(1-naphthoyl)pyrrole by substitution at the nitrogen~~
13 ~~atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,~~
14 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
15 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
16 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
17 ~~in the pyrrole ring to any extent, whether or not~~
18 ~~substituted in the naphthyl ring to any extent. Examples~~
19 ~~of this structural class include, but are not limited to,~~
20 ~~JWH 030, JWH 145, JWH 146, JWH 307, and JWH 368;~~

21 (44) (Blank); ~~Any compound structurally derived from~~
22 ~~1-(1-naphthylmethyl)indene by substitution at the~~
23 ~~3-position of the indene ring by alkyl, haloalkyl,~~
24 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
25 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
26 ~~2-(4-morpholinyl)ethyl whether or not further substituted~~

1 ~~in the indene ring to any extent, whether or not~~
2 ~~substituted in the naphthyl ring to any extent. Examples~~
3 ~~of this structural class include, but are not limited to,~~
4 ~~JWH-176;~~

5 (45) (Blank); ~~Any compound structurally derived from~~
6 ~~3-phenylacetylindole by substitution at the nitrogen atom~~
7 ~~of the indole ring with alkyl, haloalkyl, alkenyl,~~
8 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
9 ~~halide, 1 (N methyl 2 piperidinyl)methyl, or~~
10 ~~2 (4 morpholinyl)ethyl, whether or not further substituted~~
11 ~~in the indole ring to any extent, whether or not~~
12 ~~substituted in the phenyl ring to any extent. Examples of~~
13 ~~this structural class include, but are not limited to,~~
14 ~~JWH-167, JWH-250, JWH-251, and RCS-8;~~

15 (46) (Blank); ~~Any compound structurally derived from~~
16 ~~2-(3-hydroxycyclohexyl)phenol by substitution at the~~
17 ~~5 position of the phenolic ring by alkyl, haloalkyl,~~
18 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
19 ~~alkyl aryl halide, 1 (N methyl 2 piperidinyl)methyl, or~~
20 ~~2-(4-morpholinyl)ethyl, whether or not substituted in the~~
21 ~~cyclohexyl ring to any extent. Examples of this structural~~
22 ~~class include, but are not limited to, CP-47, 497 and its~~
23 ~~C8 homologue (cannabicyclohexanol);~~

24 (46.1) (Blank); ~~Any compound structurally derived from~~
25 ~~3-(benzoyl)indole with substitution at the nitrogen atom~~
26 ~~of the indole ring by an alkyl, haloalkyl, alkenyl,~~

~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group whether or not further
substituted in the indole ring to any extent and whether
or not substituted in the phenyl ring to any extent.
Examples of this structural class include, but are not
limited to, AM 630, AM 2233, AM 694, Pravadoline (WIN
48,098), and RCS 4;~~

(47) (Blank);

(48) (Blank);

(49) (Blank);

(50) (Blank);

(51) (Blank);

(52) (Blank);

(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

Some trade or other names: 2C-T-7;

(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-E;

(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
trade or other names: 2C-D;

(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-C;

(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
or other names: 2C-I;

(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-T-2;

1 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.

2 Some trade or other names: 2C-T-4;

3 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
4 other names: 2C-H;

5 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
6 trade or other names: 2C-N;

7 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
8 trade or other names: 2C-P;

9 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
10 Some trade or other names: 2C-G;

11 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
12 phenethylamine referred to in subparagraphs (20.1), (53),
13 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
14 (53.8), (53.9), and (53.10) including, but not limited to,
15 25I-NBOMe and 25C-NBOMe;

16 (54) 5-Methoxy-N,N-diisopropyltryptamine;

17 (55) (Blank);

18 (56) (Blank);

19 (57) (Blank);

20 (58) (Blank);

21 (59) (Blank); ~~3-cyclopropoylindole with substitution~~
22 ~~at the nitrogen atom of the indole ring by alkyl,~~
23 ~~haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,~~
24 ~~aryl halide, alkyl aryl halide,~~
25 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
26 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~

1 ~~on the indole ring to any extent, whether or not~~
2 ~~substituted on the cyclopropyl ring to any extent:~~
3 ~~including, but not limited to, XLR11, UR144, FUB-144;~~

4 (60) (Blank); ~~3-adamantoylindole with substitution at~~
5 ~~the nitrogen atom of the indole ring by alkyl, haloalkyl,~~
6 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
7 ~~alkyl aryl halide, 1 (N methyl 2 piperidinyl)methyl, or~~
8 ~~2 (4 morpholinyl)ethyl, whether or not further substituted~~
9 ~~on the indole ring to any extent, whether or not~~
10 ~~substituted on the adamantyl ring to any extent:~~
11 ~~including, but not limited to, AB-001;~~

12 (61) (Blank); ~~N-(adamantyl) indole 3-carboxamide with~~
13 ~~substitution at the nitrogen atom of the indole ring by~~
14 ~~alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
15 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
16 ~~1 (N methyl 2 piperidinyl)methyl, or~~
17 ~~2 (4 morpholinyl)ethyl, whether or not further substituted~~
18 ~~on the indole ring to any extent, whether or not~~
19 ~~substituted on the adamantyl ring to any extent:~~
20 ~~including, but not limited to, APICA/2NE-1, STS-135;~~

21 (62) (Blank); ~~N-(adamantyl) indazole 3-carboxamide~~
22 ~~with substitution at a nitrogen atom of the indazole ring~~
23 ~~by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
24 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
25 ~~1 (N methyl 2 piperidinyl)methyl, or~~
26 ~~2 (4 morpholinyl)ethyl, whether or not further substituted~~

1 ~~on the indazole ring to any extent, whether or not~~
2 ~~substituted on the adamantyl ring to any extent:~~
3 ~~including, but not limited to, AKB48, 5F-AKB48,~~

4 (63) (Blank); ~~1H-indole-3-carboxylic acid~~
5 ~~8-quinolinyl ester with substitution at the nitrogen atom~~
6 ~~of the indole ring by alkyl, haloalkyl, alkenyl,~~
7 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
8 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
9 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
10 ~~on the indole ring to any extent, whether or not~~
11 ~~substituted on the quinoline ring to any extent:~~
12 ~~including, but not limited to, PB22, 5F-PB22, FUB-PB-22,~~

13 (64) (Blank); ~~3-(1-naphthoyl)indazole with~~
14 ~~substitution at the nitrogen atom of the indazole ring by~~
15 ~~alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
16 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
17 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
18 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
19 ~~on the indazole ring to any extent, whether or not~~
20 ~~substituted on the naphthyl ring to any extent: including,~~
21 ~~but not limited to, THJ-018, THJ-2201,~~

22 (65) (Blank); ~~2-(1-naphthoyl)benzimidazole with~~
23 ~~substitution at the nitrogen atom of the benzimidazole~~
24 ~~ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
25 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
26 ~~1-(N-methyl-2-piperidinyl)methyl, or~~

1 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
2 ~~on the benzimidazole ring to any extent, whether or not~~
3 ~~substituted on the naphthyl ring to any extent: including,~~
4 ~~but not limited to, FUBIMINA;~~

5 (66) (Blank); ~~N-(1-amino-3-methyl-1-oxobutan-2-yl)-~~
6 ~~1H-indazole-3-carboxamide with substitution on the~~
7 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
8 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
9 ~~alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
10 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
11 ~~on the indazole ring to any extent: including, but not~~
12 ~~limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;~~

13 (67) (Blank); ~~N-(1-amino-3,3-dimethyl-1-oxobutan-~~
14 ~~2-yl)-1H-indazole-3-carboxamide with substitution on the~~
15 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
16 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
17 ~~alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
18 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
19 ~~on the indazole ring to any extent: including, but not~~
20 ~~limited to, ADB-PINACA, ADB-FUBINACA;~~

21 (68) (Blank); ~~N-(1-amino-3,3-dimethyl-1-oxobutan-~~
22 ~~2-yl)-1H-indole-3-carboxamide with substitution on the~~
23 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
24 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
25 ~~alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
26 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~

1 ~~on the indole ring to any extent: including, but not~~
2 ~~limited to, ADBICA, 5F ADBICA;~~

3 (69) (Blank); ~~N-(1-amino-3-methyl-1-oxobutan-2-~~
4 ~~yl)-1H-indole-3-carboxamide with substitution on the~~
5 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
6 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
7 ~~alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
8 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
9 ~~on the indole ring to any extent: including, but not~~
10 ~~limited to, ABICA, 5F ABICA;~~

11 (70) (Blank); ~~Methyl 2-(1H-indazole-3-carboxamido)-3-~~
12 ~~methylbutanoate with substitution on the nitrogen atom of~~
13 ~~the indazole ring by alkyl, haloalkyl, alkenyl,~~
14 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl~~
15 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
16 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
17 ~~on the indazole ring to any extent: including, but not~~
18 ~~limited to, AMB, 5F AMB;~~

19 (71) (Blank); ~~Methyl 2-(1H-indazole-3-carboxamido)-~~
20 ~~3,3-dimethylbutanoate with substitution on the nitrogen~~
21 ~~atom of the indazole ring by alkyl, haloalkyl, alkenyl,~~
22 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl~~
23 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
24 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
25 ~~on the indazole ring to any extent: including, but not~~
26 ~~limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;~~

1 (72) (Blank); ~~Methyl 2-(1H-indole-3-carboxamido)-3-~~
2 ~~methylbutanoate with substitution on the nitrogen atom of~~
3 ~~the indole ring by alkyl, haloalkyl, alkenyl,~~
4 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
5 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
6 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
7 ~~on the indazole ring to any extent: including, but not~~
8 ~~limited to, MMB018, MMB2201, and AMB-CHIMICA;~~

9 (73) (Blank); ~~Methyl 2-(1H-indole-3-carboxamido)-3,3-~~
10 ~~dimethylbutanoate with substitution on the nitrogen atom~~
11 ~~of the indole ring by alkyl, haloalkyl, alkenyl,~~
12 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
13 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
14 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
15 ~~on the indazole ring to any extent: including, but not~~
16 ~~limited to, MDMA-CHIMICA;~~

17 (74) (Blank); ~~N-(1-Amino-1-oxo-3-phenylpropan-~~
18 ~~-2-yl)-1H-indazole-3-carboxamide with substitution on the~~
19 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
20 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
21 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
22 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
23 ~~on the indazole ring to any extent: including, but not~~
24 ~~limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;~~

25 (75) (Blank); ~~N-(1-Amino-1-oxo-3-phenylpropan-~~
26 ~~-2-yl)-1H-indazole-3-carboxamide with substitution on the~~

1 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
2 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
3 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
4 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
5 ~~on the indazole ring to any extent: including, but not~~
6 ~~limited to, APP-PICA and 5-fluoro APP-PICA;~~

7 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
8 4-AcO-DMT;

9 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
10 name 5-MeO-MIPT;

11 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

12 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

13 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

14 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
15 (4-HO-MiPT);

16 (82) (Blank); ~~Fluorophenylpiperazine;~~

17 (83) Methoxetamine;

18 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
19 ethcathinone).

20 (e) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 substances having a depressant effect on the central nervous
24 system, including its salts, isomers, and salts of isomers
25 whenever the existence of such salts, isomers, and salts of
26 isomers is possible within the specific chemical designation:

- 1 (1) mecloqualone;
- 2 (2) methaqualone; and
- 3 (3) gamma hydroxybutyric acid.

4 (f) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances having a stimulant effect on the central nervous
8 system, including its salts, isomers, and salts of isomers:

- 9 (1) Fenethylamine;
- 10 (2) N-ethylamphetamine;
- 11 (3) Aminorex (some other names:
12 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
13 4-5-dihydro-5-phenyl-2-oxazolamine) and its
14 salts, optical isomers, and salts of optical isomers;

- 15 (4) Methcathinone (some other names:
16 2-methylamino-1-phenylpropan-1-one;
17 Ephedrone; 2-(methylamino)-propiofenone;
18 alpha-(methylamino)propiofenone; N-methylcathinone;
19 methcathinone; Monomethylpropion; UR 1431) and its
20 salts, optical isomers, and salts of optical isomers;

- 21 (5) Cathinone (some trade or other names:
22 2-aminopropiofenone; alpha-aminopropiofenone;
23 2-amino-1-phenyl-propanone; norephedrone);

- 24 (6) N,N-dimethylamphetamine (also known as:
25 N,N-alpha-trimethyl-benzeneethanamine;
26 N,N-alpha-trimethylphenethylamine);

1 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
2 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

3 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

4 (9) Halogenated amphetamines and
5 methamphetamines - any compound derived from either
6 amphetamine or methamphetamine through the substitution
7 of a halogen on the phenyl ring, including, but not
8 limited to, 2-fluoroamphetamine, 3-
9 fluoroamphetamine and 4-fluoroamphetamine;

10 (10) Aminopropylbenzofuran (APB):
11 including 4-(2-Aminopropyl) benzofuran, 5-
12 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
13 benzofuran, and 7-(2-Aminopropyl) benzofuran;

14 (11) Aminopropyldihydrobenzofuran (APDB):
15 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
16 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
17 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
18 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

19 (12) Methylaminopropylbenzofuran
20 (MAPB): including 4-(2-methylaminopropyl)
21 benzofuran, 5-(2-methylaminopropyl)benzofuran,
22 6-(2-methylaminopropyl)benzofuran
23 and 7-(2-methylaminopropyl)benzofuran; ~~-~~

24 (13) Methylaminopropyldihydrobenzofuran
25 (MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-
26 N-methylpropan-2-amine.

1 (g) Temporary listing of substances subject to emergency
2 scheduling. Any material, compound, mixture, or preparation
3 that contains any quantity of the following substances:

4 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
5 (benzylfentanyl), its optical isomers, isomers, salts, and
6 salts of isomers;

7 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
8 phenylpropanamide (thenylfentanyl), its optical isomers,
9 salts, and salts of isomers.

10 (h) Synthetic cathinones. Unless specifically excepted,
11 any chemical compound which is not approved by the United
12 States Food and Drug Administration or, if approved, is not
13 dispensed or possessed in accordance with State or federal
14 law, not including bupropion, structurally derived from
15 2-aminopropan-1-one by substitution at the 1-position with
16 either phenyl, naphthyl, or thiophene ring systems, whether or
17 not the compound is further modified in one or more of the
18 following ways:

19 (1) by substitution in the ring system to any extent
20 with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or
21 halide substituents, whether or not further substituted in
22 the ring system by one or more other univalent
23 substituents. Examples of this class include, but are not
24 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

25 (2) by substitution at the 3-position with an acyclic
26 alkyl substituent. Examples of this class include, but are

1 not limited to, 2-methylamino-1-phenylbutan-1-one
2 (buphedrone); or

3 (3) by substitution at the 2-amino nitrogen atom with
4 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
5 inclusion of the 2-amino nitrogen atom in a cyclic
6 structure. Examples of this class include, but are not
7 limited to, Dimethylcathinone, Ethcathinone, and
8 α -Pyrrolidinopropiophenone (α -PPP); or

9 Any other synthetic cathinone which is not approved by the
10 United States Food and Drug Administration or, if approved, is
11 not dispensed or possessed in accordance with State or federal
12 law.

13 (i) Synthetic cannabinoids or piperazines. Any synthetic
14 cannabinoid or piperazine which is not approved by the United
15 States Food and Drug Administration or, if approved, which is
16 not dispensed or possessed in accordance with State and
17 federal law.

18 (1) As used in this Section, "synthetic cannabinoid"
19 includes, but is not limited to, any compound, as
20 identified in a report from an accredited forensic
21 laboratory, that is structurally derived from any one or
22 more of the following compounds:

23 (A) Any compound structurally derived from
24 3-(1-naphthoyl)indole or
25 1H-indol-3-yl-(1-naphthyl)methane by substitution at
26 the nitrogen atom of the indole ring by alkyl,

1 haloalkyl, alkenyl, cycloalkylmethyl,
2 cycloalkylethyl, aryl halide, alkyl aryl halide,
3 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl whether or not further
5 substituted in the indole ring to any extent, whether
6 or not substituted in the naphthyl ring to any extent.
7 Examples of this structural class include, but are not
8 limited to, JWH-018, AM-2201, JWH-175, JWH-184, and
9 JWH-185;

10 (B) 3-(1-naphthoyl)pyrrole by substitution at the
11 nitrogen atom of the pyrrole ring by alkyl, haloalkyl,
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
13 halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted in the pyrrole ring to any extent, whether
17 or not substituted in the naphthyl ring to any extent.
18 Examples of this structural class include, but are not
19 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
20 JWH-368;

21 (C) 1-(1-naphthylmethyl)indene by substitution at
22 the 3-position of the indene ring by alkyl, haloalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
24 halide, alkyl aryl halide,
25 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl whether or not further

1 substituted in the indene ring to any extent, whether
2 or not substituted in the naphthyl ring to any extent.
3 Examples of this structural class include, but are not
4 limited to, JWH-176;

5 (D) 3-phenylacetylindole by substitution at the
6 nitrogen atom of the indole ring with alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, aryl halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further
11 substituted in the indole ring to any extent, whether
12 or not substituted in the phenyl ring to any extent.
13 Examples of this structural class include, but are not
14 limited to, JWH-167, JWH-250, JWH-251, and RCS-8;

15 (E) 2-(3-hydroxycyclohexyl)phenol by substitution
16 at the 5-position of the phenolic ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl,
18 cycloalkylethyl, aryl halide, alkyl aryl halide,
19 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not substituted in
21 the cyclohexyl ring to any extent. Examples of this
22 structural class include, but are not limited to, CP
23 47, 497 and its C8 homologue (cannabicyclohexanol);

24 (F) 3-(benzoyl) indole with substitution at the
25 nitrogen atom of the indole ring by an alkyl,
26 haloalkyl, alkenyl, cycloalkylmethyl,

1 cycloalkylethyl, aryl halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl group whether or not further
4 substituted in the indole ring to any extent and
5 whether or not substituted in the phenyl ring to any
6 extent. Examples of this structural class include, but
7 are not limited to, AM-630, AM-2233, AM-694,
8 Pravadoline (WIN 48,098), and RCS-4;

9 (G) 3-cyclopropoylindole with substitution at the
10 nitrogen atom of the indole ring by alkyl, haloalkyl,
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
12 halide, alkyl aryl halide,
13 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further
15 substituted on the indole ring to any extent, whether
16 or not substituted on the cyclopropyl ring to any
17 extent, including, but not limited to, XLR11, UR144,
18 FUB-144;

19 (H) 3-adamantoylindole with substitution at the
20 nitrogen atom of the indole ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
22 halide, alkyl aryl halide,
23 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further
25 substituted on the indole ring to any extent, whether
26 or not substituted on the adamantyl ring to any

1 extent, including, but not limited to, AB-001;

2 (I) N-(adamantyl)-indole-3-carboxamide with
3 substitution at the nitrogen atom of the indole ring
4 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, aryl halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further
8 substituted on the indole ring to any extent, whether
9 or not substituted on the adamantyl ring to any
10 extent, including, but not limited to, APICA/2NE-1,
11 STS-135;

12 (J) N-(adamantyl)-indazole-3-carboxamide with
13 substitution at a nitrogen atom of the indazole ring
14 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole ring to any extent,
19 whether or not substituted on the adamantyl ring to
20 any extent, including, but not limited to, AKB48,
21 5F-AKB48;

22 (K) 1H-indole-3-carboxylic acid 8-quinolinyl ester
23 with substitution at the nitrogen atom of the indole
24 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25 cycloalkylethyl, aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further
2 substituted on the indole ring to any extent, whether
3 or not substituted on the quinoline ring to any
4 extent, including, but not limited to, PB22, 5F-PB22,
5 FUB-PB-22;

6 (L) 3-(1-naphthoyl)indazole with substitution at
7 the nitrogen atom of the indazole ring by alkyl,
8 haloalkyl, alkenyl, cycloalkylmethyl,
9 cycloalkylethyl, aryl halide, alkyl aryl halide,
10 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further
12 substituted on the indazole ring to any extent,
13 whether or not substituted on the naphthyl ring to any
14 extent, including, but not limited to, THJ-018,
15 THJ-2201;

16 (M) 2-(1-naphthoyl)benzimidazole with
17 substitution at the nitrogen atom of the benzimidazole
18 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
19 cycloalkylethyl, aryl halide, alkyl aryl halide,
20 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further
22 substituted on the benzimidazole ring to any extent,
23 whether or not substituted on the naphthyl ring to any
24 extent, including, but not limited to, FUBIMINA;

25 (N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
26 indazole-3-carboxamide with substitution on the

1 nitrogen atom of the indazole ring by alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, aryl halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further
6 substituted on the indazole ring to any extent,
7 including, but not limited to, AB-PINACA, AB-FUBINACA,
8 AB-CHMINACA;

9 (O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
10 1H-indazole-3-carboxamide with substitution on the
11 nitrogen atom of the indazole ring by alkyl,
12 haloalkyl, alkenyl, cycloalkylmethyl,
13 cycloalkylethyl, aryl halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted on the indazole ring to any extent,
17 including, but not limited to, ADB-PINACA,
18 ADB-FUBINACA;

19 (P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
20 1H-indole-3-carboxamide with substitution on the
21 nitrogen atom of the indole ring by alkyl, haloalkyl,
22 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
23 halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further
26 substituted on the indole ring to any extent,

1 including, but not limited to, ADBICA, 5F-ADBICA;

2 (Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
3 indole-3-carboxamide with substitution on the nitrogen
4 atom of the indole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
6 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further
8 substituted on the indole ring to any extent,
9 including, but not limited to, ABICA, 5F-ABICA;

10 (R) Methyl 2-(1H-indazole-3-carboxamido)-
11 3-methylbutanoate with substitution on the nitrogen
12 atom of the indazole ring by alkyl, haloalkyl,
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
14 halide, alkyl aryl halide,
15 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further
17 substituted on the indazole ring to any extent,
18 including, but not limited to, AMB, 5F-AMB;

19 (S) Methyl 2-(1H-indazole-3-carboxamido)-
20 3,3-dimethylbutanoate with substitution on the
21 nitrogen atom of the indazole ring by alkyl,
22 haloalkyl, alkenyl, cycloalkylmethyl,
23 cycloalkylethyl, aryl halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further
26 substituted on the indazole ring to any extent,

1 including, but not limited to, 5-fluoro-MDMB-PINACA,
2 MDMB-FUBINACA;

3 (T) Methyl 2-(1H-indole-3-carboxamido)-3-
4 methylbutanoate with substitution on the nitrogen atom
5 of the indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
7 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further
9 substituted on the indole ring to any extent,
10 including, but not limited to, MMB018, MMB2201, and
11 AMB-CHMICA;

12 (U) Methyl 2-(1H-indole-3-carboxamido)-3,3-
13 dimethylbutanoate with substitution on the nitrogen
14 atom of the indole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
16 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole indole ring to any extent,
19 including, but not limited to, MDMB-CHMICA;

20 (V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
21 indazole-3-carboxamide with substitution on the
22 nitrogen atom of the indazole ring by alkyl,
23 haloalkyl, alkenyl, cycloalkylmethyl,
24 cycloalkylethyl, aryl halide, alkyl aryl halide,
25 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further

1 substituted on the indazole ring to any extent,
2 including, but not limited to, APP-CHMINACA,
3 5-fluoro-APP-PINACA;

4 (W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
5 1H-indole-3-carboxamide with substitution on the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
8 halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further
11 substituted on the indole ring to any extent,
12 including, but not limited to, APP-PICA and
13 5-fluoro-APP-PICA;

14 (X) 1H-indazole-3-carboxylic acid 8-quinolinyl
15 ester with substitution at the nitrogen atom of the
16 indazole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
18 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further
20 substituted on the inazdole ring to any extent,
21 whether or not substituted on the quinoline ring to
22 any extent, including, but not limited to, SDB-005,
23 5-F-SDB-005;

24 (2) As used in this Section, "synthetic piperazine"
25 includes, but is not limited to, any of the following
26 compounds and their positional isomers:

- 1 (A) N-Benzylpiperazine (BZP);
2 (B) Trifluoromethylphenylpiperazine (TFMPP);
3 (C) Fluorophenylpiperazine;
4 (D) Chlorophenylpiperazine.

5 (j) Unless specifically excepted or listed in another
6 schedule, any chemical compound which is not approved by the
7 United States Food and Drug Administration or, if approved, is
8 not dispensed or possessed in accordance with State or federal
9 law, and is derived from the following structural classes and
10 their salts:

11 (1) Benzodiazepine class: A fused 1,4-diazepine and
12 benzene ring structure with a phenyl connected to the
13 1,4-diazepine ring, with any substitution(s) or
14 replacement(s) on the 1,4-diazepine or benzene ring, any
15 substitution(s) on the phenyl ring, or any combination
16 thereof. Examples of this class include but are not
17 limited to: Clonazolam, Flualprazolam; or

18 (2) Thienodiazepine class: A fused 1,4-diazepine and
19 thiophene ring structure with a phenyl connected to the
20 1,4-diazepine ring, with any substitution(s) or
21 replacement(s) on the 1,4-diazepine or thiophene ring, any
22 substitution(s) on the phenyl ring, or any combination
23 thereof. Examples of this class include but are not
24 limited to: Etizolam.

25 (k) Fentanyl-related substances.

26 (1) As used in this Section, "fentanyl-related

1 substance" means any compound, as identified in a report
2 from an accredited forensic laboratory, unless
3 specifically excepted or listed under another schedule,
4 that is not approved by the United States Food and Drug
5 Administration or, if approved, is not dispensed or
6 possessed in accordance with State or federal law and that
7 is structurally derived from fentanyl
8 (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-
9 propanamide) by one or more of the following
10 modifications:

11 (A) replacement of the phenyl portion of the
12 phenethyl group by any monocycle, whether or not
13 further substituted in or on the monocycle;

14 (B) substitution in or on the phenethyl group with
15 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl,
16 amino, or nitro groups;

17 (C) substitution in or on the piperidine ring with
18 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo,
19 haloalkyl, amino, or nitro groups;

20 (D) replacement of the aniline ring with any
21 aromatic monocycle whether or not further substituted
22 in or on the aromatic monocycle; or

23 (E) replacement of the N-propionyl group by
24 another acyl group.

25 (2) "Fentanyl-related substance" includes, but is not
26 limited to, the following substances:

- 1 (A) Acetyl-alpha-methylfentanyl;
- 2 (B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta-
3 phenyl)ethyl-4-piperidyl) propionanilide;
4 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
5 piperidine;
- 6 (C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
7 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 8 (D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
9 phenethyl)-4-piperidinyl]-N-phenylpropanamide
- 10 (E) 3-Methylfentanyl (N-[3-methyl-1-(2-
11 phenylethyl)-4-piperidyl]-N-phenylpropanamide);
- 12 (F) 3-Methylthiofentanyl (N-[(3-methyl-1-
13 (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 14 (G) Para-fluorofentanyl (N-(4-fluorophenyl)-
15 N-[1-(2-phenethyl)-4-piperidinyl]propanamide);
- 16 (H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-
17 4-piperidinyl]-propanamide);
- 18 (I) Beta-hydroxy-3-methylfentanyl (other name:
19 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-
20 4-piperidinyl]-N-phenylpropanamide);
- 21 (J) Furanyl fentanyl (FU-F);
- 22 (K) Butyryl fentanyl;
- 23 (L) Valeryl fentanyl;
- 24 (M) Acetyl fentanyl;
- 25 (N) Beta-hydroxy-thiofentanyl;
- 26 (O) Acrylfentanyl (acryloylfentanyl);

- 1 (P) Cyclopropyl fentanyl;
2 (Q) Crotonyl fentanyl;
3 (R) Methoxyacetyl fentanyl;
4 (S) Pentanoyl fentanyl;
5 (T) Cyclopentyl fentanyl;
6 (U) Isobutyryl fentanyl;
7 (V) Benzodioxolefentanyl;
8 (W) Tetrahydrofuran fentanyl.

9 (Source: P.A. 103-245, eff. 1-1-24.)

10 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

11 Sec. 206. (a) The controlled substances listed in this
12 Section are included in Schedule II.

13 (b) Unless specifically excepted or unless listed in
14 another schedule, any of the following substances whether
15 produced directly or indirectly by extraction from substances
16 of vegetable origin, or independently by means of chemical
17 synthesis, or by combination of extraction and chemical
18 synthesis:

19 (1) Opium and opiates, and any salt, compound,
20 derivative or preparation of opium or opiate, excluding
21 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
22 nalmefene, naloxone, and naltrexone, and their respective
23 salts, but including the following:

24 (i) Raw Opium;

25 (ii) Opium extracts;

- 1 (iii) Opium fluid extracts;
- 2 (iv) Powdered opium;
- 3 (v) Granulated opium;
- 4 (vi) Tincture of opium;
- 5 (vii) Codeine;
- 6 (viii) Ethylmorphine;
- 7 (ix) Etorphine Hydrochloride;
- 8 (x) Hydrocodone;
- 9 (xi) Hydromorphone;
- 10 (xii) Metopon;
- 11 (xiii) Morphine;
- 12 (xiii.5) 6-Monoacetylmorphine;
- 13 (xiv) Oxycodone;
- 14 (xv) Oxymorphone;
- 15 (xv.5) Tapentadol;
- 16 (xvi) Thebaine;
- 17 (xvii) Thebaine-derived butorphanol.
- 18 (xviii) Methorphan, except drug products
- 19 containing dextromethorphan that may be dispensed
- 20 pursuant to a prescription order of a practitioner and
- 21 are sold in compliance with the safety and labeling
- 22 standards as set forth by the United States Food and
- 23 Drug Administration, or drug products containing
- 24 dextromethorphan that are sold in solid, tablet,
- 25 liquid, capsule, powder, thin film, or gel form and
- 26 which are formulated, packaged, and sold in dosages

1 and concentrations for use as an over-the-counter drug
2 product. For the purposes of this Section,
3 "over-the-counter drug product" means a drug that is
4 available to consumers without a prescription and sold
5 in compliance with the safety and labeling standards
6 as set forth by the United States Food and Drug
7 Administration.

8 (2) Any salt, compound, isomer, derivative or
9 preparation thereof which is chemically equivalent or
10 identical with any of the substances referred to in
11 subparagraph (1), but not including the isoquinoline
12 alkaloids of opium;

13 (3) Opium poppy and poppy straw;

14 (4) Coca leaves and any salt, compound, isomer, salt
15 of an isomer, derivative, or preparation of coca leaves
16 including cocaine or ecgonine, and any salt, compound,
17 isomer, derivative, or preparation thereof which is
18 chemically equivalent or identical with any of these
19 substances, but not including decocainized coca leaves or
20 extractions of coca leaves which do not contain cocaine or
21 ecgonine (for the purpose of this paragraph, the term
22 "isomer" includes optical, ~~positional~~ and geometric
23 isomers);

24 (5) Concentrate of poppy straw (the crude extract of
25 poppy straw in either liquid, solid or powder form which
26 contains the phenanthrine alkaloids of the opium poppy).

1 (c) Unless specifically excepted or unless listed in
2 another schedule any of the following opiates, including their
3 isomers, esters, ethers, salts, and salts of isomers, whenever
4 the existence of these isomers, esters, ethers and salts is
5 possible within the specific chemical designation, dextrorphan
6 excepted:

7 (1) Alfentanil;

8 (1.1) Carfentanil;

9 (1.2) Thiafentanil;

10 (2) Alphaprodine;

11 (3) Anileridine;

12 (4) Bezitramide;

13 (5) Bulk Dextropropoxyphene (non-dosage forms);

14 (6) Dihydrocodeine;

15 (7) Diphenoxylate;

16 (8) Fentanyl;

17 (9) Sufentanil;

18 (9.5) Remifentanil;

19 (10) Isomethadone;

20 (11) (Blank);

21 (12) Levorphanol (Levorphan);

22 (13) Metazocine;

23 (14) Methadone;

24 (15) Methadone-Intermediate,

25 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;

26 (16) Moramide-Intermediate,

1 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
2 acid;

3 (17) Pethidine (meperidine);

4 (18) Pethidine-Intermediate-A,
5 4-cyano-1-methyl-4-phenylpiperidine;

6 (19) Pethidine-Intermediate-B,
7 ethyl-4-phenylpiperidine-4-carboxylate;

8 (20) Pethidine-Intermediate-C,
9 1-methyl-4-phenylpiperidine-4-carboxylic acid;

10 (21) Phenazocine;

11 (22) Piminodine;

12 (23) Racemethorphan;

13 (24) (Blank);

14 (25) Levo-alpha-acetylmethadol (some other names:
15 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).

16 (d) Unless specifically excepted or unless listed in
17 another schedule, any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 substances having a stimulant effect on the central nervous
20 system:

21 (1) Amphetamine, its salts, optical isomers, and salts
22 of its optical isomers;

23 (2) Methamphetamine, its salts, isomers, and salts of
24 its isomers;

25 (3) Phenmetrazine and its salts;

26 (4) Methylphenidate;

1 (5) Lisdexamfetamine.

2 (e) Unless specifically excepted or unless listed in
3 another schedule, any material, compound, mixture, or
4 preparation which contains any quantity of the following
5 substances having a depressant effect on the central nervous
6 system, including its salts, isomers, and salts of isomers
7 whenever the existence of such salts, isomers, and salts of
8 isomers is possible within the specific chemical designation:

9 (1) Amobarbital;

10 (2) Secobarbital;

11 (3) Pentobarbital;

12 (4) Pentazocine;

13 (5) Phencyclidine;

14 (6) Gluthethimide;

15 (7) (Blank).

16 (f) Unless specifically excepted or unless listed in
17 another schedule, any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 substances:

20 (1) Immediate precursor to amphetamine and
21 methamphetamine:

22 (i) Phenylacetone

23 Some trade or other names: phenyl-2-propanone;

24 P2P; benzyl methyl ketone; methyl benzyl ketone.

25 (2) Immediate precursors to phencyclidine:

26 (i) 1-phenylcyclohexylamine;

1 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

2 (3) Nabilone.

3 (Source: P.A. 100-368, eff. 1-1-18.)

4 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

5 (Text of Section before amendment by P.A. 103-881)

6 Sec. 208. (a) The controlled substances listed in this
7 Section are included in Schedule III.

8 (b) Unless specifically excepted or unless listed in
9 another schedule, any material, compound, mixture, or
10 preparation which contains any quantity of the following
11 substances having a stimulant effect on the central nervous
12 system, including its salts, isomers (whether optical
13 position, or geometric), and salts of such isomers whenever
14 the existence of such salts, isomers, and salts of isomers is
15 possible within the specific chemical designation;

16 (1) Those compounds, mixtures, or preparations in
17 dosage unit form containing any stimulant substances
18 listed in Schedule II which compounds, mixtures, or
19 preparations were listed on August 25, 1971, as excepted
20 compounds under Title 21, Code of Federal Regulations,
21 Section 308.32, and any other drug of the quantitative
22 composition shown in that list for those drugs or which is
23 the same except that it contains a lesser quantity of
24 controlled substances;

25 (2) Benzphetamine;

1 (3) Chlorphentermine;

2 (4) Clortermine;

3 (5) Phendimetrazine.

4 (c) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances having a potential for abuse associated with a
8 depressant effect on the central nervous system:

9 (1) Any compound, mixture, or preparation containing
10 amobarbital, secobarbital, pentobarbital or any salt
11 thereof and one or more other active medicinal ingredients
12 which are not listed in any schedule;

13 (2) Any suppository dosage form containing
14 amobarbital, secobarbital, pentobarbital or any salt of
15 any of these drugs and approved by the Federal Food and
16 Drug Administration for marketing only as a suppository;

17 (3) Any substance which contains any quantity of a
18 derivative of barbituric acid, or any salt thereof:

19 (3.1) Aprobarbital;

20 (3.2) Butabarbital (secbutabarbital);

21 (3.3) Butalbital;

22 (3.4) Butobarbital (butethal);

23 (4) Chlorhexadol;

24 (5) Methyprylon;

25 (6) Sulfondiethylmethane;

26 (7) Sulfonethylmethane;

1 (8) Sulfonylmethane;

2 (9) Lysergic acid;

3 (10) Lysergic acid amide;

4 (10.1) Tiletamine or zolazepam or both, or any salt of
5 either of them.

6 Some trade or other names for a tiletamine-zolazepam
7 combination product: Telazol.

8 Some trade or other names for Tiletamine:

9 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

10 Some trade or other names for zolazepam:

11 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
12 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrzapon.

13 (11) Any material, compound, mixture or preparation
14 containing not more than 12.5 milligrams of pentazocine or
15 any of its salts, per 325 milligrams of aspirin;

16 (12) Any material, compound, mixture or preparation
17 containing not more than 12.5 milligrams of pentazocine or
18 any of its salts, per 325 milligrams of acetaminophen;

19 (13) Any material, compound, mixture or preparation
20 containing not more than 50 milligrams of pentazocine or
21 any of its salts plus naloxone HCl USP 0.5 milligrams, per
22 dosage unit;

23 (14) Ketamine;

24 (15) Thiopental.

25 (d) Nalorphine.

26 (d.5) Buprenorphine.

1 (e) Unless specifically excepted or unless listed in
2 another schedule, any material, compound, mixture, or
3 preparation containing limited quantities of any of the
4 following narcotic drugs, or their salts calculated as the
5 free anhydrous base or alkaloid, as set forth below:

6 (1) not more than 1.8 grams of codeine per 100
7 milliliters or not more than 90 milligrams per dosage
8 unit, with an equal or greater quantity of an isoquinoline
9 alkaloid of opium;

10 (2) not more than 1.8 grams of codeine per 100
11 milliliters or not more than 90 milligrams per dosage
12 unit, with one or more active non-narcotic ingredients in
13 recognized therapeutic amounts;

14 (3) (blank);

15 (4) (blank);

16 (5) not more than 1.8 grams of dihydrocodeine per 100
17 milliliters or not more than 90 milligrams per dosage
18 unit, with one or more active, non-narcotic ingredients in
19 recognized therapeutic amounts;

20 (6) not more than 300 milligrams of ethylmorphine per
21 100 milliliters or not more than 15 milligrams per dosage
22 unit, with one or more active, non-narcotic ingredients in
23 recognized therapeutic amounts;

24 (7) not more than 500 milligrams of opium per 100
25 milliliters or per 100 grams, or not more than 25
26 milligrams per dosage unit, with one or more active,

1 non-narcotic ingredients in recognized therapeutic
2 amounts;

3 (8) not more than 50 milligrams of morphine per 100
4 milliliters or per 100 grams with one or more active,
5 non-narcotic ingredients in recognized therapeutic
6 amounts.

7 (f) Anabolic steroids, except the following anabolic
8 steroids that are exempt:

9 (1) Androgyn L.A.;

10 (2) Andro-Estro 90-4;

11 (3) depANDROGYN;

12 (4) DEPO-T.E.;

13 (5) depTESTROGEN;

14 (6) Duomone;

15 (7) DURATESTRIN;

16 (8) DUO-SPAN II;

17 (9) Estratest;

18 (10) Estratest H.S.;

19 (11) PAN ESTRA TEST;

20 (12) Premarin with Methyltestosterone;

21 (13) TEST-ESTRO Cypionates;

22 (14) Testosterone Cyp 50 Estradiol Cyp 2;

23 (15) Testosterone Cypionate-Estradiol Cypionate
24 injection; and

25 (16) Testosterone Enanthate-Estradiol Valerate
26 injection.

1 (g) Hallucinogenic substances.

2 (1) Dronabinol (synthetic) in sesame oil and
3 encapsulated in a soft gelatin capsule in a U.S. Food and
4 Drug Administration approved product. Some other names for
5 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
6 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
7 (-)-delta-9-(trans)-tetrahydrocannabinol.

8 (2) (Reserved).

9 (h) The Department may except by rule any compound,
10 mixture, or preparation containing any stimulant or depressant
11 substance listed in subsection (b) from the application of all
12 or any part of this Act if the compound, mixture, or
13 preparation contains one or more active medicinal ingredients
14 not having a stimulant or depressant effect on the central
15 nervous system, and if the admixtures are included therein in
16 combinations, quantity, proportion, or concentration that
17 vitiate the potential for abuse of the substances which have a
18 stimulant or depressant effect on the central nervous system.
19 (Source: P.A. 100-368, eff. 1-1-18.)

20 (Text of Section after amendment by P.A. 103-881)

21 Sec. 208. (a) The controlled substances listed in this
22 Section are included in Schedule III.

23 (b) Unless specifically excepted or unless listed in
24 another schedule, any material, compound, mixture, or
25 preparation which contains any quantity of the following

1 substances having a stimulant effect on the central nervous
2 system, including its salts, isomers (whether optical
3 position, or geometric), and salts of such isomers whenever
4 the existence of such salts, isomers, and salts of isomers is
5 possible within the specific chemical designation;

6 (1) Those compounds, mixtures, or preparations in
7 dosage unit form containing any stimulant substances
8 listed in Schedule II which compounds, mixtures, or
9 preparations were listed on August 25, 1971, as excepted
10 compounds under Title 21, Code of Federal Regulations,
11 Section 308.32, and any other drug of the quantitative
12 composition shown in that list for those drugs or which is
13 the same except that it contains a lesser quantity of
14 controlled substances;

15 (2) Benzphetamine;

16 (3) Chlorphentermine;

17 (4) Clortermine;

18 (5) Phendimetrazine.

19 (c) Unless specifically excepted or unless listed in
20 another schedule, any material, compound, mixture, or
21 preparation which contains any quantity of the following
22 substances having a potential for misuse associated with a
23 depressant effect on the central nervous system:

24 (1) Any compound, mixture, or preparation containing
25 amobarbital, secobarbital, pentobarbital or any salt
26 thereof and one or more other active medicinal ingredients

1 which are not listed in any schedule;

2 (2) Any suppository dosage form containing
3 amobarbital, secobarbital, pentobarbital or any salt of
4 any of these drugs and approved by the Federal Food and
5 Drug Administration for marketing only as a suppository;

6 (3) Any substance which contains any quantity of a
7 derivative of barbituric acid, or any salt thereof:

8 (3.1) Aprobarbital;

9 (3.2) Butabarbital (secbutabarbital);

10 (3.3) Butalbital;

11 (3.4) Butobarbital (butethal);

12 (4) Chlorhexadol;

13 (5) Methyprylon;

14 (6) Sulfondiethylmethane;

15 (7) Sulfonethylmethane;

16 (8) Sulfonmethane;

17 (9) Lysergic acid;

18 (10) Lysergic acid amide;

19 (10.1) Tiletamine or zolazepam or both, or any salt of
20 either of them.

21 Some trade or other names for a tiletamine-zolazepam
22 combination product: Telazol.

23 Some trade or other names for Tiletamine:

24 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

25 Some trade or other names for zolazepam:

26 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

1 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrzapon.

2 (11) Any material, compound, mixture or preparation
3 containing not more than 12.5 milligrams of pentazocine or
4 any of its salts, per 325 milligrams of aspirin;

5 (12) Any material, compound, mixture or preparation
6 containing not more than 12.5 milligrams of pentazocine or
7 any of its salts, per 325 milligrams of acetaminophen;

8 (13) Any material, compound, mixture or preparation
9 containing not more than 50 milligrams of pentazocine or
10 any of its salts plus naloxone HCl USP 0.5 milligrams, per
11 dosage unit;

12 (14) Ketamine;

13 (15) Thiopental; ~~-~~

14 (16) Xylazine.

15 (d) Nalorphine.

16 (d.5) Buprenorphine.

17 (e) Unless specifically excepted or unless listed in
18 another schedule, any material, compound, mixture, or
19 preparation containing limited quantities of any of the
20 following narcotic drugs, or their salts calculated as the
21 free anhydrous base or alkaloid, as set forth below:

22 (1) not more than 1.8 grams of codeine per 100
23 milliliters or not more than 90 milligrams per dosage
24 unit, with an equal or greater quantity of an isoquinoline
25 alkaloid of opium;

26 (2) not more than 1.8 grams of codeine per 100

1 milliliters or not more than 90 milligrams per dosage
2 unit, with one or more active non-narcotic ingredients in
3 recognized therapeutic amounts;

4 (3) (blank);

5 (4) (blank);

6 (5) not more than 1.8 grams of dihydrocodeine per 100
7 milliliters or not more than 90 milligrams per dosage
8 unit, with one or more active, non-narcotic ingredients in
9 recognized therapeutic amounts;

10 (6) not more than 300 milligrams of ethylmorphine per
11 100 milliliters or not more than 15 milligrams per dosage
12 unit, with one or more active, non-narcotic ingredients in
13 recognized therapeutic amounts;

14 (7) not more than 500 milligrams of opium per 100
15 milliliters or per 100 grams, or not more than 25
16 milligrams per dosage unit, with one or more active,
17 non-narcotic ingredients in recognized therapeutic
18 amounts;

19 (8) not more than 50 milligrams of morphine per 100
20 milliliters or per 100 grams with one or more active,
21 non-narcotic ingredients in recognized therapeutic
22 amounts.

23 (f) Anabolic steroids, except the following anabolic
24 steroids that are exempt:

25 (1) Androgyn L.A.;

26 (2) Andro-Estro 90-4;

- 1 (3) depANDROGYN;
- 2 (4) DEPO-T.E.;
- 3 (5) depTESTROGEN;
- 4 (6) Duomone;
- 5 (7) DURATESTRIN;
- 6 (8) DUO-SPAN II;
- 7 (9) Estratest;
- 8 (10) Estratest H.S.;
- 9 (11) PAN ESTRA TEST;
- 10 (12) Premarin with Methyltestosterone;
- 11 (13) TEST-ESTRO Cypionates;
- 12 (14) Testosterone Cyp 50 Estradiol Cyp 2;
- 13 (15) Testosterone Cypionate-Estradiol Cypionate
- 14 injection; and
- 15 (16) Testosterone Enanthate-Estradiol Valerate
- 16 injection.

17 (g) Hallucinogenic substances.

18 (1) Dronabinol (synthetic) in sesame oil and
19 encapsulated in a soft gelatin capsule in a U.S. Food and
20 Drug Administration approved product. Some other names for
21 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
22 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
23 (-)-delta-9-(trans)-tetrahydrocannabinol.

24 (2) (Reserved).

25 (h) The Department may except by rule any compound,
26 mixture, or preparation containing any stimulant or depressant

1 substance listed in subsection (b) from the application of all
2 or any part of this Act if the compound, mixture, or
3 preparation contains one or more active medicinal ingredients
4 not having a stimulant or depressant effect on the central
5 nervous system, and if the admixtures are included therein in
6 combinations, quantity, proportion, or concentration that
7 vitiate the potential for misuse of the substances which have
8 a stimulant or depressant effect on the central nervous
9 system.

10 (Source: P.A. 103-881, eff. 1-1-25.)

11 (720 ILCS 570/309.1 new)

12 Sec. 309.1. Xylazine exemptions. Notwithstanding the
13 scheduling of xylazine as a Schedule III controlled substance,
14 xylazine shall not be considered a controlled substance when:

15 (1) used by licensed Illinois veterinarians dispensing
16 or prescribing for, or administering to, a nonhuman
17 species of a drug containing xylazine that has been
18 approved by the U.S. Food and Drug Administration;

19 (2) used by licensed Illinois veterinarians dispensing
20 or prescribing for, or administering to, a nonhuman
21 species that is permissible under the Federal Food, Drug,
22 and Cosmetic Act;

23 (3) manufactured, distributed, or used as an active
24 pharmaceutical ingredient for manufacturing an animal drug
25 approved under the Federal Food, Drug, and Cosmetic Act;

1 (4) used by a licensed certified euthanasia technician
2 employed by a certified euthanasia agency; or
3 (5) used by a wildlife biologist engaged in legal or
4 authorized fieldwork under the indirect supervision of a
5 veterinarian.

6 Section 95. No acceleration or delay. Where this Act makes
7 changes in a statute that is represented in this Act by text
8 that is not yet or no longer in effect (for example, a Section
9 represented by multiple versions), the use of that text does
10 not accelerate or delay the taking effect of (i) the changes
11 made by this Act or (ii) provisions derived from any other
12 Public Act.

13 Section 99. Effective date. This Act takes effect January
14 1, 2026.